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Introduction
Two evening clinics were run as part of a waiting list initiative in the east area of 
Glasgow Clinical Psychology service. The first clinic ran from October 2002 to 
March 2003, the second ran from September 2003 to January 2004. A third 
evening clinic is planned for 2005, funding is currently being negotiated.
Improving waiting times is a key priority for the NHS in Scotland (Jones, 2003). 
The subject of waiting times in the NHS has been an important issue for a 
number of years. The most recent work in this area has been reviewing waiting 
lists, and looking at more effective ways of managing them (Scottish Executive, 
2003; Audit Scotland, 2002).
A review of waiting lists in Scotland said that ‘waiting lists and waiting times are 
important measures of how the health service is responding to demand. They 
highlight where there are delays in particular parts of the health system’ (Audit 
Scotland, 2002. Page 14). The review looked at: the arrangements for placing 
patients on waiting lists, the monitoring of lists and the way in which these are 
kept up to date, the extent to which services are using central guidance, and 
whether any methods of list management had lead to inappropriate delays to 
treatment.
Following this review some recommendations were made. Firstly, patients 
should be routinely informed about the waiting times. Secondly, to reduce the 
DNA rate, patients should be contacted regularly to ensure that circumstances 
have not changed. Thirdly, all services should have early warning systems and 
plans to identify and manage potential waiting list problems. Finally, services
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should give information to patients, GPs, and the public about waiting lists and 
waiting times.
The Scottish Executive (2003) produced a good practice guide to managing 
waiting times. Their guidance supported the recommendations of the Audit 
Scotland review (2002) and built on the commitments in the White Paper 
‘Partnership for Care’. The ‘Managing Waiting Times’ report (Scottish 
Executive, 2003. Page 6) claimed that waiting times were important to patients 
because: The patient’s condition could deteriorate while waiting, and in some 
cases the effectiveness of the proposed treatment may be reduced. The 
experience of waiting could be distressing. The patient’s family life and 
employment circumstances could be adversely affected by waiting. The report 
noted that ‘a short period of waiting which is managed in the patient’s best 
interests could support the scheduling of routine and emergency care and 
ensure the most urgent patients are seen first’, but that ‘excessive waiting times 
must be reduced’(Page 6). The report stated that services must:
• Manage demand by ensuring each referral represents the most 
appropriate decision for the care of the individual patient.
• Manage the queue by ensuring waiting lists are well managed and 
patients are called for treatment in appropriate order.
• Manage capacity by providing efficient and effective services that meet 
the level of demand from appropriate referrals.
• Provide leadership by ensuring that all parts of the local NHS work 
together to achieve waiting time improvements in the best interests of 
patients.
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The waiting list for Clinical Psychology services in the east area of Glasgow had 
been identified as a problem. To prevent the wait from becoming excessive 
ways of managing the waiting list were investigated. Looking at the current 
literature two points seemed most relevant; firstly, that ‘all services should have 
early warning systems and plans to identify and manage potential waiting list 
problems’ (Audit Scotland, 2002. Page 46), and secondly that the service must 
‘manage capacity by providing efficient and effective services that meet the 
level of demand from appropriate referrals’ (Scottish Executive, 2003. Page 7).
It was decided that running evening clinics in addition to the routine daytime 
service would be a way of managing capacity in the Clinical Psychology service. 
Evening clinics are a short-term way to increase clinical activity, treat a backlog 
of patients on a waiting list, and improve waiting times.
Future evening clinics are being proposed and negotiations regarding funding 
are currently taking place in the east area of Glasgow. This audit provides an 
overall view of clinical activity at the evening clinics. The data displayed and 
discussed in this report should inform decisions about the future use and 
provision of evening clinics to be made at a management level.
Aims
The aim of this audit was to provide a description of the evening clinics, 
focussing on the uptake of this additional service.
Audit Questions
• How many appointments were available at the evening clinics?
• How many new people were seen at the evening clinics?
• How many of the appointments at the evening clinics were taken up?
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• How many people attended the evening clinics?
• How many times did people attend the evening clinics?
• How many people were discharged at the end of the evening clinics?
• How many people carried on in the service once the clinics had finished?
• What was the immediate impact on the waiting list in the usual day-time 
service?
Methodology
The majority of data for this audit were taken from a ‘Waiting List Initiative 
Database’ kept by the east area of Glasgow Clinical Psychology service. This 
database was designed specifically to record audit data and was kept in 
addition to routine data collection methods. Separate files were kept for each 
clinic. The database was examined closely. Any gaps in the data were 
followed up and completed from paper-based records. Information recorded on 
the database included:
• A weekly breakdown of activity for each clinician
• A record of annual leave and sick leave for each clinician
• How many patients attended, did not attend (DNA) and cancelled for 
each clinician
• Time used for supervision and administration
• How many patients attended, DNA and cancelled each week
• The outcome at the end of each clinic -  how many patients were 
discharged and how many carried on into the usual day-time service
The sample consisted of two hundred and twenty-four patients in total, one 
hundred and seven from the first clinic and one hundred and seventeen from
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the second clinic. Patients were taken from the top of the routine waiting list, 
i.e. those who were longest waiting, no exclusion criteria or screening methods 
were applied.
The evening clinics were analysed separately using an array of descriptive 
statistics, and then compared to see if any differences emerged. Following this 
the two sets of information were combined to give an overall picture of activity at 
the evening clinics. The Patient Information Management System (PIMS) was 
used to obtain data regarding rates of attendance, non-attendance and 
cancellation for a sample of the patients attending the usual day-time service. 
PIMS was also used to collate figures for waiting list numbers and waiting times. 
The PIMS system was used as a daily data collection tool, but was not 
specifically designed to collect audit data. Some clinicians did not complete 
PIMS records and often accurate figures were not available from this system.
Results
The audit questions listed in the introduction are addressed in order.
• How many appointments were available at the evening clinics?
The first evening clinic was run by four clinicians for six months, providing one 
hundred and forty-six time slots. A one hour session is defined as one ‘time 
slot’. Patients were seen in one hundred and eleven (76%) of these slots and 
the other thirty-five (24%) were used for supervision and administration.
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The second evening clinic was run by three clinicians for the first month and 
then five clinicians for four months, providing one hundred and fifty-nine time 
slots, one hundred and thirty-one (82%) of which were used for patients and 
twenty-eight (18%) for supervision and administration. Together the clinics 
provided three hundred and five time slots, two hundred and forty-two (79%) of 
these were used to see patients.
• How many new people were seen at the evening clinics?
• How many of the appointments at the evening clinics were taken up?
• How many people attended the evening clinics?
• How many times did people attend the evening clinics?
In total two hundred and twenty-four people were offered appointments at the 
evening clinics between October 2002 and January 2004, with one hundred and 
seven appointments at the first clinic and one hundred and seventeen at the 
second. This resulted in two hundred and twenty-four new patients being taken 
off the waiting list. Table one shows the use of these appointments for both 
clinics and an overall picture.
Table 1 -  Breakdown of Appointment Outcomes.
Attended Did Not Attend Cancelled
Clinic 1 62 34 11
Clinic 2 72 20 25
Overall 134 54 36
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Table one shows that the majority of appointments were attended, with the 
levels of non-attendance and cancellation varying between the two clinics. The 
graph below gives on overall picture of how appointments were used by 
patients.
Graph 1 -  Appointment use
Graph one shows that over half (60%) of the appointments given at the evening 
clinics were attended. Cancellations and non-attendance made up the 
remaining 40% of appointment use. The number of times that people attended 
appointments during the evening clinics varied. On average people attended 
two sessions each out of the appointments that were offered, this figure takes 
into account those patients who did not attend, who cancelled, and also those 
who attended one or more than one appointment.
Cancelled
16%
Did Not Attend 
24% Attended 60%
The rates of attendance, non-attendance and cancellation were compared to 
the rates for the usual day-time service.
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Table 2 -  A Comparison of Appointment Outcomes for Evening and Daytime
Clinics.
Attended Did Not Attend Cancelled
Daytime Clinic 160 54 36
Evening Clinic 134 58 32
Table two illustrates that attendance for the day-time service was slightly higher, 
one hundred and sixty (64%) compared to one hundred and thirty-four (60%) for 
the evening clinics. The rates of non-attendance were similar fifty-four (23%) 
for the day-time service and fifty-eight (24%) for the evening clinics. Rates of 
cancellation were also similar with thirty-six (13%) for the day-time service and 
thirty-two (16%) for the evening clinics. Figures for the day-time service were 
obtained by looking at attendance, non-attendance and cancellation rates for 
the last two hundred and fifty new contacts on the Patient Information 
Management System (PIMS) in March 2005. As previously mentioned using 
the PIMS system to obtain audit data did have limitations, therefore this 
comparison can be used to give a very general overview of the differences 
between the usual day-time service and the evening clinics.
• How many people were discharged at the end of the evening clinics?
• How many people carried on in the service once the clinics had finished?
Following these appointments patients took various routes through the service. 
Some patients did not attend any appointments or cancelled and did not require 
any further input, they were discharged. Other patients attended one or more 
appointments and were discharged from the service at various points.
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Table 3 -  Outcome at the end of Evening Clinics
Discharged Day-time Appointment
C linic 1 34 63
Clinic 2 32 10
Overall 66 73
Table three shows that at the end of the first evening clinic thirty-four (32%) 
patients were discharged and sixty-three (59%) carried on into usual day-time 
appointments. When the second clinic ended thirty-two (27%) patients were 
discharged, and ten (9%) patients carried on into the usual day-time service. 
Overall sixty-six patients were discharged (29%) and seventy-three (33%) 
required further input. Other patients who had been offered appointments were 
discharged before the end of the clinics for various reasons.
• What was the immediate impact on the waiting list in the usual day-time 
service?
The five months before the start of the first evening clinic (May to September 
2002) the average number of people on the east area waiting list was five 
hundred and fifty-eight. In the five months after the first clinic and before the 
second clinic (April to August 2003) the waiting list was five hundred and forty- 
one, a three percent reduction. In the five months after the second evening 
clinic ended (February to June 2004) the waiting list was four hundred and 
seventy-two, a fifteen percent reduction.
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Conclusions & Recommendations
The results across both clinics were compared on a number of dimensions. 
Firstly, the number of appointments available was similar for both clinics, one 
hundred and eleven and one hundred and thirty-one, giving an overall total of 
two hundred and forty-two. Both clinics took a similar amount of new patients 
off the waiting list. The rates of attendance, non-attendance and cancellation 
were also similar for clinics one and two. The amount of sessions used for 
patients, supervision and administration were alike for both clinics. At the end 
of the evening clinics thirty-two percent of patients were discharged from the 
first clinic and twenty-seven percent from the second, again similar values.
The main difference between the two evening clinics emerged when looking at 
the figures for patients who carried on into the usual day-time service; fifty-nine 
percent from clinic one carried on into day-time appointments compared to only 
nine percent of patients from clinic two. There are many reasons why this 
difference may have occurred, some of which can be speculated upon. Two 
obvious differences that existed between the two clinics were that more 
sessions were available at the second clinic and more experienced clinicians 
ran the sessions. Many variables are present in every Clinical Psychology 
service such as case complexity, waiting list pressures, departmental guidelines 
regarding number of treatment sessions, experience of clinicians, etc. All of 
these factors could have played a part in this difference between the two clinics.
An overall view of the clinics revealed that they provided three hundred and five 
time slots, 79% of which were used to see patients. Two hundred and twenty- 
four new patients were taken off the waiting list. Sixty percent of the
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appointments given at the evening clinics were attended. People attended an 
average of two sessions each out of the appointments that were offered. At the 
end of the clinics twenty-nine percent of patients were discharged and thirty- 
three percent were offered further input.
The overall view of attendance, non attendance and cancellation rates at the 
evening clinics was compared to rates for the usual day-time appointments. 
Attendance for the day-time service was slightly higher, sixty-four percent 
compared to sixty percent for the evening clinics. The rates of non-attendance 
and cancellation were similar. The evening clinics appeared to be taken up in a 
similar way to the daytime appointments. As previously mentioned there were 
differences between data sets for the routine daytime service and the evening 
clinics. The data collected for the evening clinics was collected on a separate 
database designed to record audit information. Data for the daytime service 
was collected on the PIMS system which was used for routine information 
recording. The PIMS system was not completed by all clinicians and often had 
technical faults which made the data inaccurate. Due to the differences in data 
sets for the evening clinics and the daytime service it was not considered to be 
meaningful to look at the statistical significance of any differences between the 
two services.
The immediate impact of the evening clinics upon the usual day-time waiting 
list was examined. There was a fifteen percent reduction in the waiting list 
following the second evening clinic, but only a three percent reduction after the 
first clinic. These figures are only approximate and must be treated with caution 
as numerous factors can impact upon a waiting list.
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Factors such as referral rates, staffing levels, complexity of cases, etc. can all 
impact upon the waiting list. One difference between the two clinics which may 
have had an impact is the difference in numbers of patients who carried on into 
the usual day-time service. At the end of clinic one fifty-nine percent of patients 
carried on into day-time appointments compared to only nine percent of patients 
from clinic two. The large percentage of patients who were offered further input 
at the end of the first clinic could have resulted in less patients being taken off 
the waiting list as appointments would be taken up by patients from the evening 
clinic. At the end of the second clinic fewer patients were offered further input in 
the day-time service, possibly leaving more available appointments for people 
on the waiting list to be seen in the usual day-time service.
Another factor which could have had an impact on the waiting list was the fact 
that extra clinicians who did not routinely work in the daytime service worked at 
the evening clinics. The routine daytime service continued as normal, but was 
supplemented by additional appointments in the evening. The daytime service 
was under staffed at the time of the clinics due to unfilled vacancies. By 
providing extra sessions in the evening the service prevented the waiting list 
from becoming any longer, and reduced it by fifteen percent at the end of the 
second clinic. These staffing levels could explain the small reduction in the 
waiting list following the first clinic (3%); instead of a large reduction in the 
waiting list the service prevented an increase.
When considering the overall view of the evening clinic data certain suggestions 
for the future could be made. One suggestion is to shift the focus of the
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evening clinics to a type of assessment or screening exercise. Given that in 
total twenty-nine percent of patients were discharged and thirty-three percent 
required further input at the end of the evening clinics, this leaves thirty-eight 
percent who were discharged for various reasons before the end of the clinics. 
An initial assessment clinic could help to identify those patients who require 
input and those who would be willing to attend sessions. This way of using the 
clinical time could allow a large number of patients to be assessed in 
preparation for offering day-time appointments.
The practical and ethical issues related to evening clinics must also be 
considered. Safety for members of staff working after usual hours is one such 
issue. A suitable building with extra secretarial staff was used to run the first 
two evening clinics. This type of arrangement would need to be made for any 
future clinics. Extra staff time was another practical issue. Staff came from 
other services to provide sessions in the evening clinics, in addition to clinical 
and secretarial staff from the routine daytime service. This meant extra funding 
to pay all staff at the appropriate rate for working out of hours. These factors 
must be considered alongside the patient data when looking at the future uses 
of the evening clinics.
Further data from the third evening clinic, which is being negotiated at present, 
could be added to the existing data set. It would be useful to look at any trends 
that emerged from the data, especially in terms of the number of patients who 
carried on into the day-time service given that there is a notable difference 
clinics one and two. Any other differences and similarities would also provide 
extra information to help guide the future direction of evening clinics. The aim
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of this audit was to provide a description of the evening clinics, focussing on the 
uptake of this additional service. Further investigation into other factors which 
have an influence on the waiting list would also help to provide a more accurate 
picture of the true impact of running evening clinics as a waiting list initiative. 
Further work on comparing the routine daytime service and the evening clinics 
would also help to determine how viable the evening clinics were.
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Abstract
This systematic review aimed to address the following questions: ‘What is the 
prevalence of anxiety and depression in men with prostate cancer?’ and ‘Is 
there a relationship between anxiety, depression and sexual dysfunction in men 
with prostate cancer?’ The purpose of the review was to investigate the quality 
of studies looking at levels of anxiety, depression and sexual dysfunction in a 
systematic way. An electronic search of suitable health databases was 
completed using five key terms to reflect the main components of the 
systematic review question. Twelve studies were then identified using inclusion 
and exclusion criteria and included in this review. The methodological quality of 
each of the twelve studies was examined using assessment criteria adapted 
from the Scottish Intercollegiate Guidelines Network (SIGN) 50 ‘A Guideline 
Developers’ Handbook’ [1], Reported prevalence levels for ‘clinically significant’ 
anxiety ranged from 32.6% to 6.7%. Prevalence rates for ‘clinically significant’ 
depression ranged from 2% to 27%. Reported prevalence of sexual dysfunction 
ranged from 40 to 80%. Limitations of the current literature are discussed and 
suggestions for future research are proposed.
Keywords -  Prostate, cancer, anxiety, depression, sexual dysfunction.
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Introduction
Prostate Cancer
Prostate cancer affects nearly thirty-two thousand men per year in the United 
Kingdom and causes ten thousand deaths per year [2]. Being diagnosed with 
and treated for prostate cancer involves a complex set of biological and 
psychological factors. Men who are treated for prostate cancer and survive 
often face many treatment-specific side effects afterwards [3]. One side effect 
that is commonly reported is sexual dysfunction [4, 5]. All prostate cancer 
treatments involve varying degrees of medical intervention. These interventions 
range from surgery to regular check ups and PSA tests (active monitoring). 
Surgery, radiotherapy, brachytherapy and hormone therapy are all effective in 
the treatment of prostate cancer but have associated side effects. Side effects 
include: urinary incontinence, sexual dysfunction, bowel problems, hot flushes, 
breast swelling and tenderness, weight gain and osteoporosis. Urinary 
incontinence and sexual dysfunction are caused by all four of the treatments 
described above. Sexual dysfunction includes: loss of libido, infertility, erectile 
dysfunction, inability to orgasm, etc. The need for a better understanding of 
patients’ psychological needs at various stages of prostate cancer diagnosis 
and treatment has been highlighted [4].
Psychological Distress
Many studies have reported that cancer and psychological problems, such as 
anxiety and depression, often co-occur [6]. General theoretical psychological 
models of why people may experience anxiety and depression have been used 
in relation to cancer patients [7, 8]. Models of Post-traumatic Stress Disorder
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have also been used to explain some of the psychological symptoms that 
people experience following a diagnosis of cancer and subsequent treatment 
[9]. Manzanera et al. (2003) assessed a sample of 54 patients with various 
types of cancer using the Hospital Anxiety and Depression Scale [11]. They 
found that 32% reported depressive disorders and 30% anxiety disorders [10]. 
Kollner, Lautenschlager and Pajonk (2004) reported in their review paper that 
the frequency of co-occurrence is approximately 50% and that depression, 
anxiety and possibly post-traumatic stress disorder are the problems most 
relevant in prostate cancer.
Sexual Dysfunction
Matthew et al. (2005) reviewed the literature related to sexual dysfunction 
following radical prostatectomy from 1966 to 2004. They found that several 
studies reported that 44% to 75% of men experienced sexual dysfunction, of 
whom more than 60% experienced distress because of their sexual dysfunction 
problems. Weber and Sherwill-Navarro (2005) reviewed 30 years of research 
on the ‘psychosocial consequences’ of prostate cancer. They stated that 
‘survivorship’ in prostate cancer patients is commonly complicated by long-term 
disease-specific side effects, such as sexual and urinary dysfunction. Studies 
have shown that the psychological impact of prostate cancer continues long 
after the diagnosis and treatment phases have been completed. Baker, 
Denniston, Smith and West (2005) used the Cancer Problems in Living Scale 
(CPILS) to assess 752 patients, 97 of whom had prostate cancer. They found 
that a year on from diagnosis: 68% of patients were concerned about their 
illness returning, 58% had fears about the future, and 41% reported sexual 
dysfunction as a major concern.
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A small, but increasing number of studies have begun to address the 
psychological impact of prostate cancer. In earlier studies the physical and 
psychological effects of being diagnosed with and treated for prostate cancer 
were mainly assessed using health-related quality of life measures [13]. Many 
papers have noted that studies of health-related quality of life focussed on 
physical well-being and paid relatively little attention to psychological functioning 
[14,15,16]. Bennett and Badger (2005) stated that the clinical significance of 
psychological distress experienced by men with prostate cancer had yet to be 
adequately addressed in the research literature. At the time of their project, 
Hervouet et al. (2005) identified four studies which evaluated the prevalence of 
depression and anxiety in prostate cancer patients using validated instruments; 
all of them used the Hospital Anxiety and Depression Scale. They noted 
prevalence rates of depression ranging from 3% to 15% and anxiety rates from 
11% to 33%.
Crawford et al. (2001) administered the Hospital Anxiety and Depression Scale 
to a large non-clinical sample of adults in the United Kingdom. They found that 
on the HADS anxiety sub-scale the mean score was 6.14 and on the HADS 
depression sub-scale the mean score was 3.68. Crawford at al. [17] reported 
that on the HADS anxiety sub-scale 20.6% of the population scored between 8- 
10 (mild), 10% scored in the moderate range (11-15), and 2.6% scored 16 or 
above (severe). On the HADS depression sub-scale 7.8% of the population 
were in the mild range (8-10), 2.9% scored 11-15 (moderate), and 0.7% scored 
in the severe range (16 or above). These figures provide a useful point of 
comparison for prevalence rates in clinical populations.
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The primary aim is to systematically review the current literature addressing the 
prevalence of anxiety and depression in prostate cancer patients. A secondary 
aim is to examine the prevalence of sexual dysfunction, and if there is any 
relationship between sexual dysfunction and anxiety and/or depression.
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Method
Objective
This systematic review aimed to address the following questions:
• What is the prevalence of anxiety and depression in men with prostate 
cancer?
• Is there a relationship between anxiety, depression and sexual 
dysfunction in men with prostate cancer?
Search Strategy
The following electronic databases were searched during this review:
Medline (1950-2007)
Psychlnfo (1806-2007)
CINAHL (1982-2007)
EMBASE (1980-2007)
All EMB Reviews, including CDSR, ACP Journal Club, DARE, CCTR 
Search Terms
The electronic search used five key terms to reflect the main components of the 
systematic review question.
1) Prostate
2) Cancer
3) Anxiety
4) Depression
5) Sexual Dysfunction
6) 1,2,3 & 4 combined using AND
7) 1,2,3, 4 & 5 combined using AND
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All duplicates were removed. The reference lists for articles were also 
reviewed. Hand searches of Psycho-oncology and the Journal of Psychosocial 
Oncology were also completed (1997-2007).
Inclusion Criteria
• Participants aged 18 years or over
• Participants with a primary diagnosis of Prostate Cancer
• Studies using an outcome measure for anxiety and/or depression
• Peer reviewed journal articles
• English Language journal articles
• Studies addressing the incidence and prevalence of anxiety or 
depression in prostate cancer patients
• Studies addressing the incidence and prevalence of sexual dysfunction 
in prostate cancer patients
Results
Search Results
Initial searches using electronic databases generated 436 possible papers. The 
titles and abstracts of these papers were reviewed. Four hundred and six 
papers were considered not to be relevant to the review question on the basis 
of their abstracts and were excluded. Thirty papers were retained as being 
relevant to the review question. Following a hand search of key journals and 
reference lists of papers from the electronic search a further 2 papers were 
identified as potentially suitable (see Appendix 2.2).
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Excluded Studies
The full articles for the 32 potentially suitable studies were reviewed. Following 
this, a further 20 studies did not meet the inclusion criteria for this review. Nine 
of the latter papers were non English language and so were excluded. Five 
papers were letters, editorials or reviews [20, 21, 22, 23, 4]. Three studies did 
not use an outcome measure to assess anxiety and/or depression [24, 25, 26]. 
Two papers included participants whose primary diagnosis was not solely 
prostate cancer [27, 28] and were therefore, excluded. One other paper was 
not a peer reviewed journal article [29] and was also excluded.
Included Studies
Twelve studies were included in the review:
• Bisson et al., 2002 [16]
• Balderson & Towell, 2003 [30]
• Roth et al., 1998 [15]
• Lintz et al., 2003 [31]
• Hervouet et al., 2005 [19]
• Rosenfeld et al., 2004 [14]
• Cliff & MacDonagh, 2000 [32]
• Korfage et al., 2006 [33]
• Ene et al., 2006 [34]
• Steineck et al., 2002 [35]
• Sharpley & Christie, 2007 [36]
• Soloway et al., 2005 [37]
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Data Extraction
Data were extracted from each of the included studies. The data were relevant 
to the aim of the review and related to the design and quality of the study. A 
summary of the data extracted from each study is shown in Table 1.
Quality Assessment
The methodological quality of each of the 12 studies was examined using 
assessment criteria adapted from the Scottish Intercollegiate Guidelines 
Network (SIGN) 50 ‘A Guideline Developers’ Handbook’ (SIGN, 2004). The 
criteria assessed 24 factors including; research aims, hypotheses, population, 
design, outcome measures, results and analysis (see Appendix 2.3). Score 
totals ranged from 0 to 48, where individual ratings were a possible score of 0 
(Not addressed, not reported or not applicable), 1 (poorly addressed), or 2 
(adequately addressed or well covered) on each item. The reviewer and the 
independent examiner were not blind to study details, such as, author, journal 
or organisations conducting the research. Scores for each study are shown in 
Table 1.
Reliability of Quality Assessment
An independent examiner also rated all studies included in this review using the 
same quality assessment criteria. Eighty-seven percent agreement was found 
between raters. Raters met to discuss any disagreements in scoring.
Review of Studies
Studies will be discussed in ascending order of total scores. All twelve of the 
papers included in this review investigated levels of anxiety and depression in
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prostate cancer patients as a part of the study. Six of the studies included in 
the review also addressed levels of sexual dysfunction [19, 35, 31, 32, 30, 37].
Hervouet et al. (2005) investigated the prevalence of anxiety and depression in 
861 prostate cancer patients who received different treatments. They 
conducted a cross-sectional comparison of patients treated with radiotherapy, 
brachytherapy or surgery (radical prostatectomy) within the last seven years. 
Hervouet et al. (2005) used the Hospital Anxiety and Depression Scale [11] to 
assess levels of anxiety and depression. The HADS was considered to be a 
reliable, valid and sensitive measure suitable for use with this population. A cut 
off score of 7 or higher on the HADS anxiety or depression subscales was used 
to indicate the presence or absence of clinically significant levels of depression 
or anxiety. A total HADS score of 15 or more was used to identify clinically 
significant levels of global psychological distress. These cut offs were taken 
from previous studies with cancer populations [15, 38]. Hervouet et al. (2005) 
reported that 23.7% of their total sample had clinically significant levels of 
anxiety, 17% were above the cut off for depression, and 14.6% above the cut 
off for global psychological distress.
The treatment groups in this study were not well matched and significant 
differences existed between them on a number of demographic and medical 
factors. Patients were not randomised into treatment groups and a control 
group was not recruited for this study. Hervouet et al. (2005) reported that 
radiotherapy patients generally had a poorer prognosis and were more likely to 
have co morbid illnesses than the other two treatment groups. However, 
radiotherapy patients were reported to have significantly higher levels of
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depression and global psychological distress than brachytherapy or surgery 
patients, after controlling for these covariates. Radiotherapy patients were also 
found to have significantly higher levels of anxiety compared to brachytherapy 
patients. Hervouet et al. (2005) concluded that radiotherapy patients were more 
likely to be at risk of psychological distress but that their study did not 
demonstrate a clear link between treatment group and level of distress.
Hervouet et al. (2005) also investigated sexual difficulties using the Prostate 
Cancer-Specific Module (PCSM), which is a supplement to the European 
Organisation for Research and Treatment of Cancer Quality-of-Life 
Questionnaire (EORTCQLQ-C30). The PCSM sexuality scale consists of 4 
items rated on a Likert scale from 1 (not at all) to 4 (a lot). Scores are then 
converted on a scale of 0-100. They used 50% as a cut off for clinically 
significant difficulties for the purposes of this study. The PCSM was translated 
by the research team but had not been empirically validated for use prior to use 
in this study. Hervouet at al. (2005) reported that 70.5% of the total patient 
sample scored above 50% on the sexual difficulties scale of the PCSM. 
Hervouet et al. (2005) reported that the finding that radical prostatectomy (RP) 
was associated with a lower likelihood of clinical levels of depression compared 
to not having surgery was surprising, considering higher prevalence of sexual 
dysfunction in the RP group. They suggest that this implies that levels of sexual 
dysfunction are not necessarily associated with mood impairments. Hervouet et 
al. (2005) did not consider the age of patients when analysing their results for 
sexual difficulties.
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Korfage et al. (2006) aimed to look at anxiety and depression in 299 prostate 
cancer patients, from pre-treatment to 5 year follow-up. Patients were non- 
randomly allocated to radical prostatectomy or radiotherapy treatment groups.
A control group was not recruited. Patients completed three validated self- 
report questionnaires; the State Trait Anxiety Inventory (STAI), the Centre for 
Epidemiological Studies Depression Scale (CES-D), and the Mental Health 
scale from the RAND 36-item Short-Form Health Survey (SF-36). The 
questionnaires were completed pre-treatment, at 6 months, 12 months and 5 
years. Following pre-treatment assessment scores on the STAI were used to 
divide patients into four groups: radical prostatectomy and high anxiety, radical 
prostatectomy and low anxiety, radiotherapy and high anxiety, radiotherapy and 
low anxiety. STAI scores below 44 were defined as ‘low anxiety’; this cut off 
was taken from previous studies [39]. Statistical analysis revealed that there 
were significant differences between the groups in relation to age, co morbid 
conditions and PSA levels. Korfage et al. (2006) reported that pre-treatment, 
28% of all patients reported clinically significant levels of anxiety, 25% of the 
surgery group and 30% of the radiotherapy group. Scores for men treated by 
surgery (radical prostatectomy) were better than those treated by radiotherapy 
for all three measures and at all four assessment points. Scores were also 
analysed in terms of ‘high anxiety’ and ‘low anxiety’ groups. No significant 
differences between ‘high anxiety’ and ‘low anxiety’ groups were found for 
scores on the CES-D. A score of 16 or above on the CES-D was considered to 
be clinically significant. At all assessment points a lower percentage of men 
treated by radical prostatectomy (9-18%) reported clinically significant levels of 
depression compared to the general population (20%). Pre-treatment (27%) 
and at 5 years follow-up (22%) the percentage of men with clinically significant
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levels of depression in the radiotherapy group was higher than the general 
population (20%). Complete data on prevalence of depression in the sample 
have not been presented in this paper. Korfage et al. (2006) did not assess 
levels of sexual dysfunction in this study.
Steineck et al. (2002) recruited 326 men, who were randomly allocated to 
radical prostatectomy (RP) or watchful-waiting (WW) treatment groups. No data 
were provided on the matching of these groups. The aim of the study was to 
evaluate symptoms and quality of life after radical prostatectomy or watchful- 
waiting. A questionnaire designed for the study was used with the CES-D and 
the trait measure from STAI added to it. No reliability or validity data for this 
measure was provided. Using the CES-D Steineck et al (2002) reported that 
7% of RP patients and 11 % of WW patients scored above the 90th percentile.
On the STAI 9% of RP and 10% of WW patients scored above 90th percentile. 
Further data regarding scores on the CES-D and STAI trait measure were not 
reported. Steineck et al. (2002) used a range of questions covering; desire, 
erection, intercourse, orgasm, ejaculation and distress from compromised 
sexuality to assess sexual dysfunction. Steineck et al. (2003) reported that 45% 
of patients in the watchful waiting group reported erectile dysfunction and 40% 
were distressed by the decline in their sexual function, compared to 80% 
reporting dysfunction and 56% reporting distress in the radical prostatectomy 
group. Full data were not provided to allow any conclusion to be made 
regarding any relationship between levels of sexual dysfunction and anxiety 
levels on the STAI or levels of depression on the CES-D.
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Bisson et al. (2002) recruited 88 newly diagnosed prostate cancer patients with 
the aim of determining the prevalence and predictors of psychological distress 
in this group. Patients completed five questionnaires, including the HADS and 
the 30-Item General Health Questionnaire (GHQ-30), before their first 
assessment and then again two weeks later. Bisson et al. used a threshold of 
10/11 on the HADS subscales and the GHQ-30 to detect clinically significant 
psychological distress, but did not state why they were using this cut off or 
quote other studies using this value. Bisson et al. (2002) stated that both 
measures had been validated for use with cancer populations and provided 
references. In the results section scores on the HADS anxiety and depression 
subscales were reported for thresholds of 7/8 and 10/11. At the first 
assessment 22% of patients scored 7 or above on the anxiety subscale, and 
10% scored 10 or above. On the depression subscale 5% of patients scored 7 
or above, and no scores were 10 or above at the first assessment. On the 
GHQ-30 scores were reported for thresholds of 4/5 and 10/11. Twenty-five 
percent of the participants scored 4 or above and 9% scored 10 or above on the 
GHQ-30 at the first assessment.
Only 61 men went on to complete the second assessment two weeks later. 
Mean scores on the HADS were compared for these 61 men. At the first 
assessment a mean score of 5.11 was obtained on the anxiety subscale, 
decreasing to 4.38 at the second assessment. On the depression subscale a 
mean score of 1.79 at first assessment increased to 2.46 at the second 
assessment. Bisson et al. (2002) reported that the HADS anxiety subscale 
score was significantly lower at the second assessment, and the depression 
subscale score was significantly higher. However, mean scores for anxiety and
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depression were below clinically significant levels at the first and second 
assessments. The GHQ-30 was not repeated at the second assessment.
Bisson et al. (2002) did not address levels of sexual dysfunction in their study.
Lintz et al. (2003) aimed to investigate the support and psychological care 
needs of men with prostate cancer. Two hundred and ten prostate cancer 
patients from a randomly pre-selected sample took part and completed four 
questionnaires including the HADS. No control group was recruited for this 
study. The mean anxiety score on the HADS subscale was 4.2. Two percent of 
patients scored 11 or more, 12.3% scored 8 to 10, and 85.7% scored less than 
8. The mean depression score on the HADS subscale was 3.4. One point four 
percent of patients scored 11 or more, 7.2% scored 8-10, 91.4% scored less 
than 8. Lintz et al. (2003) reported their results in terms of these HADS cut offs 
but did not explain how they were interpreted in the study or provide any 
references for cut off scores. They also reported that 12% of their sample had a 
‘premorbid psychiatric history’, but did not control for this when analysing and 
interpreting their data.
Lintz et al. (2003) also investigated sexual difficulties using the Prostate 
Cancer-Specific Module (PCSM). They also included further questions on 
sexuality using the Support Care Needs Survey (SCNS). On the SCNS they 
reported that 35% of men reported support needs on ‘feeling you’ve lost part of 
your manhood’, 41% for ‘changes in sexual feelings’, and 36% in ‘changes in 
sexual relationships’. On the PCSM 78% had had some difficulty ‘getting or 
maintaining an erection’, 68% had experienced ‘ejaculation problems’, 57% had
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‘felt uncomfortable about being sexually intimate’. However, despite these 
problems 89% had ‘enjoyed sex’ within the past 4 weeks.
Lintz et al. (2003) also divided their sample into men who were over 65 years 
old and men who were 65 or less for their analysis; however, they did not state 
how many men from their sample fell into each age range. They reported that 
on the SCNS men who were 65 or less had higher levels of sexual interest and 
activity. On the PCSM men who were 65 or less were more likely to feel 
uncomfortable being sexually intimate. Eighty-four percent of men who were 65 
or less reported having some interest in sex, compared to 45% over 65.
Seventy percent of men who were 65 or less reported being sexually active 
compared to 11 % over 65. It was stated that results on PCSM showed that 
men who were 65 or less were significantly more interested in sex and more 
sexually active than men who were over 65 years of age. Lintz et al. (2003) 
reported their PCSM results in a way which differed from Hervouet et al. (2005) 
making comparison problematic and full data were not provided in either study. 
Lintz et al. (2003) did not discuss the presence or absence of any relationship 
between levels of anxiety or depression and sexual dysfunction. They also did 
not control for age when analysing and interpreting HADS anxiety and 
depression scores, despite finding differences between men of over and under 
65 on the PCSM and SCNS.
Ene et al. (2006) aimed to investigate patients’ experience of pain, 
psychological distress and their health-related quality of life at baseline and 3 
months after radical prostatectomy. A sample of 140 patients completed three 
questionnaires including the HADS. Ene et al. (2006) reported that the HADS
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was a reliable and valid measure. On both the depression and anxiety 
subscales they used scores of 7 or less to indicate no distress, 8-10 to indicate 
possible anxiety or depression, and 11 plus to indicate probable anxiety or 
depression. They reported that 77% of patients had no anxiety symptoms at 
baseline compared to 92% post-surgery. Eighty-nine percent of patients did not 
have any symptoms of depression at baseline compared to 91% post-surgery. 
The mean anxiety score on the HADS subscale was 5.0 and the mean 
depression score on the HADS subscale was 3.0. At baseline 7% of patients 
scored 11 or more, 16% scored 8 to 10, and 77% scored less than 8 on the 
anxiety subscale. Two percent of patients scored 11 or more, 8% scored 8-10, 
89% scored less than 8 on the depression subscale. Scores at 3 months mean 
anxiety score on the HADS subscale was 3.0 and the mean depression score 
on the HADS subscale was 2.6. At 3 months 5% of patients scored 11 or more, 
3% scored 8 to 10, and 92% scored less than 8 on the anxiety subscale. Two 
percent of patients scored 11 or more, 7% scored 8-10, 91% scored less than 8 
on the depression subscale. Ene et al. (2006) did not investigate levels of 
sexual dysfunction in this study.
Cliff and MacDonagh (2000) recruited 135 prostate cancer patients and their 
partners in order to assess psychosocial morbidity in prostate cancer patients, 
and compare their levels of distress to their partners. They used the HADS and 
a questionnaire developed by their own research group. Cliff and MacDonagh 
(2000) aimed to develop a new questionnaire for measuring psychosocial 
morbidity in men with prostate cancer and their partners. The reliability and 
validity of this questionnaire has yet to be established. The questionnaire 
included items on sexuality, general cancer distress, social and treatment
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worries, pain and urinary symptoms. Cliff and MacDonagh (2000) reported that 
the HADS was a reliable and valid measure. On the depression subscale they 
used scores of 7 or less to indicate no distress and on the anxiety subscale 
scores of 8 or less. Scores of 8-11 indicated borderline anxiety or depression 
and scores of 11 plus indicated definite anxiety or depression. They reported 
that 6.7% of patients scored 11 or above on the anxiety subscale and 3.7% 
scored in this range on the depression subscale, indicating definite anxiety or 
depression. Eleven point one percent scored 8-11 on the anxiety subscale and 
4.4% on the depression subscale. Eighty-two point two percent of patients did 
not have any symptoms of anxiety, and 91.9% of patients did not report any 
depressive symptoms. They reported mean scores for worries about sex of 2.1 
out of 4. Results were then analysed in terms of HADS morbidity, on the 
depression subscale scores of more than 7 were taken to indicate morbidity and 
on the anxiety subscale scores of more than 8. Cliff and MacDonagh (2000) 
reported that 45% of patients below the HADS cut off on either subscale had 
worries about sexuality, and 65% above the cut off. The questionnaire did not 
include items looking at sexual dysfunction specifically.
Balderson and Towell (2003) aimed to investigate the prevalence and predictors 
of distress in men with prostate cancer. Ninety-four men with prostate cancer 
completed three questionnaires including the HADS. They used a total HADS 
score of 15 or above to indicate clinically significant psychological distress. 
Thirty-eight percent of men scored 15 or above on the HADS. The mean score 
on the anxiety subscale was 7.17, 5.09 on the depression subscale, and an 
average of 12.30 for the total HADS score. Participants were recruited from
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support groups, which Balderson and Towell argued, might account for higher 
reported levels of distress.
Balderson and Towell (2003) also included a measure of sexuality in their study 
in the Functional Assessment of Cancer Therapy-Prostate Instrument (FACT- 
P). This is a 12-item scale, with acceptable reliability and validity, including 
questions on sexuality, bowel and bladder function, and pain. Balderson and 
Towell (2003) did not report sexuality scores separately, but as part of a general 
score. They reported that the mean FACT-P score was 33.09. No cut offs or 
norms were provided for the FACT-P. Balderson and Towell (2003) found that 
prostate-specific concerns measured using the FACT-P were significantly 
related to psychological distress assessed using the HADS.
Rosenfeld et al. (2004) recruited 341 men with prostate cancer in order to 
investigate differences in physical and psychological well-being based on stage 
of cancer. Patients completed the HADS and two further questionnaires 
addressing quality of life and urinary function. Medical data were then used to 
divide the men into three groups depending on stage of cancer; localised, 
locally advanced or metastatic. HADS scores were analysed in these three 
groups. Mean scores on the HADS anxiety subscale were 10.62 for the 
localised group, 10.16 for locally advanced patients, and 11.01 for the 
metastatic group. Mean scores on the HADS depression subscale were 12.02 
for the localised group, 12.27 for locally advanced patients, and 12.65 for the 
metastatic group. Mean total scores on the HADS were 22.64 for the localised 
group, 22.43 for locally advanced patients, and 23.65 for the metastatic group. 
Rosenfeld et al. (2004) reported that there were no significant differences
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between the groups in terms of HADS scores, and concluded that prostate 
cancer stage was unrelated to HADS total or subscale scores. Numbers of 
patients above any clinical cut off scores were not provided. Rosenfeld et al.
(2004) did not investigate levels of sexual dysfunction in this study.
Sharpley and Christie (2007) recruited 183 prostate cancer patients and used 
the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale 
(SDS) to investigate current and previous levels of anxiety and depression.
They reported adequate reliability and validity of these measures, but did not 
refer to any studies that had used these measures or any reference to their 
suitability for use with cancer populations. Participants completed the SAS and 
SDS twice at one time point, once for how they felt currently and once for how 
they felt at the time of diagnosis. A raw score of greater than 36 on the SAS 
was taken as the cut off for having clinically significant anxiety. A raw score of 
above 40 on the SDS was given as the cut off for having clinically significant 
depression. When asked to rate themselves at diagnosis 20.2% of patients 
reported clinically significant anxiety symptoms, and 23.9% clinically significant 
depressive symptoms. When asked to rate themselves in the last week 12.6% 
of patients reported clinically significant anxiety symptoms, with the same 
percentage reporting clinically significant depressive symptoms. Sharpley and 
Christie (2007) did not investigate sexual dysfunction in this study.
Soloway et al. (2005) aimed to examine levels of sexual and psychological 
functioning of men with prostate cancer and their partners. They recruited 103 
men who had recently been diagnosed with prostate cancer and their partners. 
Participants completed 7 questionnaires, including the Beck Depression
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Inventory (BDI) and the Profile of Mood Sates (POMS). Patients had a mean 
score on the BDI of 5.63 and their partners had a mean score 8.13. Soloway et 
al. (2005) reported that 26.2% of patients were in the mild to moderate range on 
the BDI and 2% in the moderate to severe; none of the patients had scores in 
the severe range. They did not state the cut offs used to categorise these 
ranges. On the POMS patients had a mean score of 9.41 on the tension- 
anxiety subscale, and partners scored 11.69 on average. It was reported that 
these scores were within the normal range but no further information was 
provided.
The study by Soloway et al. (2005) was the only one, included in this review, to 
use specific measures of sexual functioning. Partners completed the Brief 
Index of Sexual Function for Women (BISF-W) and participants completed the 
Brief Sexual Function Questionnaire for Men (BSFQ) and selected questions 
from the Sexual Adjustment Questionnaire (SAQ). Patients had a mean SAQ 
total score of 51.70 and a mean BSFQ total score of 40.55. Partners had a 
mean SAQ total score of 51.75 and a mean BISF-W total score of 48.61. No 
cut off scores were given for either of these questionnaires. Soloway et al.
(2005) compared mean scores for patients and partners on all of the 
dimensions of the BSFQ and the BISF-W with means for control populations. 
They concluded that prostate cancer patients reported similar levels of sexual 
activity and performance, but lower levels of satisfaction and interest. Partners 
reported higher levels of sexual initiation and receptivity, but also higher levels 
of problems affecting sexual function. Partners reported similar levels of 
frequency of sexual activity, but lower scores than controls for sexual thoughts 
and desires, arousal, pleasure and relationship satisfaction. No information
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regarding the controls used for comparison was provided. Soloway et al. (2005) 
did not discuss the presence or absence of any relationship between levels of 
anxiety or depression and sexual dysfunction.
Roth et al. (1998) aimed to screen for psychological distress in men with 
prostate cancer. They recruited 93 patients and administered the HADS and 
‘the Distress Thermometer’, which they described as a visual analogue scale 
rating emotional distress. During analysis Roth et al. (1998) used a total HADS 
score of 15 or above to indicate clinically significant psychological distress. On 
the HADS anxiety and depression subscales a score of 7 or above was used as 
cut off for symptoms of anxiety or depression. They reported that 13% of 
patients scored at or above the cut off for the total HADS score, 32.6% scored 
at or above the cut off on the anxiety subscale, and 15.2% scored at or above 
the cut off on the depression subscale.
Discussion & Conclusions
Prevalence of Anxiety and Depression
The primary aim of this review was to systematically evaluate the current 
literature addressing the prevalence of anxiety and depression in prostate 
cancer patients.
Many of the studies included in this review used the Hospital Anxiety and 
Depression Scale [11] to assess levels of anxiety and depression in prostate 
cancer patients. Reported prevalence levels for ‘clinically significant’ anxiety 
using the HADS subscale ranged from 32.6% [15] to 6.7% [32]. Anxiety 
prevalence rates using other measures were: 28% [33] and 9/10% [35] on the
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STAI, 12.2-20.6% on the SAS [36]. Prevalence levels for ‘clinically significant’ 
depression on the HADS subscale ranged from 2% [31] to 17% [19].
Depression prevalence rates using other measures were: 7-27% on the CES-D 
[35, 33], 12.6-23.9% on the SDS [36], and 2% on the BDI [37].
Whilst investigating the reported prevalence of anxiety and depression in men 
with prostate cancer a number of methodological limitations in the existing 
literature became apparent. Firstly, many of the studies used the HADS, which 
they reported was a valid and reliable measure suitable for use with cancer 
patients. However, there was little agreement regarding scores considered to 
be ‘clinically significant’. Some studies considered scores of 7 or above on the 
HADS anxiety and depression subscales to indicate ‘clinically significant’ 
anxiety or depression [19, 15]. Other studies used scores of 8-11 to indicate 
possible or borderline anxiety or depression, and scores of 11 or more to 
indicate definite anxiety or depression [34, 31, 32, 17]. Data were often 
reported in terms of these cut-off scores rather than individual scores, making 
comparisons between studies very difficult.
Further methodological problems were noted whilst assessing the 
methodological quality of the studies included in this review. None of the 
studies included power calculations to justify their sample sizes. Only one out 
of twelve studies [35] included any sort of control group (see Table 1). Many of 
the studies did not take into account confounding variables, such as age, which 
has previously been shown to be highly correlated with psychological distress in 
prostate cancer patients [21]. Due to the range of measures used, the 
incomplete data reported, and the cut-offs considered to demonstrate ‘clinically
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significant’ anxiety or depression it was difficult to establish the prevalence of 
anxiety and depression in men with prostate cancer.
Some studies included in the review did attempt to overcome methodological 
difficulties. Three of the studies of better methodological quality, assessed 
using the methodological checklist (see Appendix 2.3 & Table 1), reported their 
results more fully [16, 19, 31]. Hervouet et al. (2005) reported their HADS data 
more fully in terms of total distress scores, and anxiety and depression subscale 
scores. Bisson et al. (2002) reported scores on the HADS anxiety and 
depression subscales for thresholds of 7/8 and 10/11. Lintz et al. (2003) 
reported HADS scores in terms of three different cut-offs, 11 or more, 8 to 10, or 
less than 8. Using the findings from these higher quality studies anxiety 
prevalence rates ranged from 23.7% [19] to 12.3% [31], prevalence rates for 
depression ranged from 17% [19] to 5% [16]. These prevalence rates did not 
appear to be much greater than rates reported by Crawford et al. (2001) for a 
non-clinical population. They found prevalence rates on the HADS anxiety sub­
scale ranging from 2.6 to 20.6%, depending on the cut-off used to identify 
clinically significant levels [17]. They reported prevalence rates on the HADS 
depression sub-scale ranging from 0.7 to 7.8%, again depending on the cut-offs 
scores used.
Sexual Dysfunction
A secondary aim of this review was to examine the prevalence of sexual 
dysfunction and any relationship between this and anxiety and/or depression.
Six out of twelve studies included in the review addressed sexual dysfunction.
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Hervouet et al. (2005) and Lintz et al. (2003) both used the PCSM to investigate 
sexual difficulties. Hervouet et al. (2005) used 50% as a cut off for clinically 
significant difficulties and reported that 70.5% of patients scored above this cut­
off on the sexual difficulties scale. Lintz et al. (2003) reported that 57-78% of 
men reported having some difficulties with sexual function; 45-84% reported 
having some interest in sex, and 11-75% reported being sexually active. They 
also reported their results in terms of men aged 65 years and under or over 65. 
Lintz et al. (2003) reported their PCSM results in a way which differed from 
Hervouet et al. (2005) making comparison problematic and full data were not 
provided in either study.
Soloway et al. (2005) used the Brief Sexual Function Questionnaire for Men 
(BSFQ) and selected questions from the Sexual Adjustment Questionnaire 
(SAQ). They reported a mean SAQ total score of 51.70 and mean BSFQ total 
score of 40.55. No cut off scores were given for either of these questionnaires. 
The other two studies [35, 32] used their own questionnaires, neither of which 
had established reliability or validity. Steineck et al. (20003) reported that 45 to 
80% of patients reported erectile dysfunction and 40 to 56% were distressed by 
the decline in their sexual function. Cliff and MacDonagh (2000) reported mean 
scores for worries about sex of 2.1 out of 4.
Cliff and MacDonagh’s (2000) study was the only one in the review to make any 
comment regarding a relationship between sexual dysfunction and anxiety 
and/or depression. They reported that 45% of patients below the HADS cut off, 
and 65% above the cut off, had worries about sexuality.
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Further methodological limitations were noted when considering sexual 
dysfunction. Studies in this review measured sexual dysfunction as part of a 
health-related quality of life measure rather than using a specific sexual function 
questionnaire, with the exception of one study [37]. Studies using the same 
measures did not provide full data and reported their results in a way which 
made comparison problematic [31, 19]. Due to the lack of valid and reliable 
measures of sexual dysfunction used and the way the data were reported it is 
difficult to reach any conclusions regarding the prevalence of sexual 
dysfunction, or if there is any relationship between sexual dysfunction and 
anxiety and/or depression.
In summary, studies reported clinically significant levels of anxiety in up to 
32.6% [15] of the sample and clinically significant levels of depression in up to 
37% [33] of participants. Although the current literature has a number of 
limitations, which have been discussed, it does provide useful information 
regarding the prevalence of anxiety and depression in men with prostate 
cancer. In terms of sexual dysfunction, data were presented in a range of ways, 
which made comparison problematic; however, studies reported that up to 78% 
[30] of the sample had difficulties in this area. Links between anxiety, 
depression and sexual dysfunction were not fully addressed by any of the 
studies; however, one study [32] reported that 65% of participants above the cut 
off for clinically significant anxiety and/or depression on the HADS had worries 
about sexuality.
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Future Research
Future research should aim to overcome the methodological limitations. Firstly, 
it would be important for future research to use valid and reliable measures of 
psychological and sexual functioning, rather than including them in a health 
related quality of life measure. Secondly, researchers should report results fully 
and in a way that makes comparison with other studies possible. Researchers 
should also aim to recruit a control group and calculate the sample size required 
for their study. This review has established that sexual dysfunction, anxiety, 
depression, and any relationship between these factors in men with prostate 
cancer require further investigation.
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Title
Life After Treatment for Prostate Cancer: Levels of Anxiety, Depression, and 
Sexual Dysfunction.
Summary
Prostate cancer affects over thirty thousand men per year in the United 
Kingdom (Cancer Research UK, 2005). Being diagnosed with and treated for 
prostate cancer involves a complex set of biological and psychological factors. 
Men who are treated for prostate cancer and survive often face many treatment 
specific side effects afterwards (Weber & Sherwill-Navarro, 2005). The side 
effect that is reported to be most common and cause most distress is sexual 
dysfunction (Matthew et al., 2005; Baker et al., 2005). Many studies have 
reported these problems, and acknowledged that sexual dysfunction has both 
physical and psychological aspects (Rosing & Berberich, 2004). More 
specifically studies have reported that patients have sexual problems, and have 
clinically significant levels of anxiety and depression (Hervouet et al., 2005) This 
study aims to assess levels of anxiety, depression and sexual dysfunction in 
men following treatment for prostate cancer. It is hypothesised that men with 
higher levels of sexual dysfunction will report higher levels of anxiety and 
depression. The study also aims to examine how coping style, quality of life, 
and perception of illness are related to each other and to levels of anxiety, 
depression, and sexual dysfunction.
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Introduction
Prostate cancer is one of the most common cancers, affecting approximately 
30,100 men every year in the United Kingdom (Cancer Research UK, 2005). 
Being diagnosed with and treated for prostate cancer involves a series of 
different medical procedures. Various psychological problems may arise at 
different stages in this process.
Symptoms of Prostate Cancer
Men who have prostate cancer may experience: problems urinating, pain in 
genitals and upon ejaculation, erection difficulties, pain in the lower back and in 
hips or pelvis, and blood in the urine.
Diagnosing Prostate Cancer
If prostate cancer is suspected a blood sample will be sent to a laboratory to 
test for Prostate Specific Antigen (PSA). A PSA test cannot detect prostate 
cancer but raised PSA levels can indicate prostate problems. A second way of 
diagnosing a prostate problem is to feel the prostate gland through the wall of 
the rectum; a Digital Rectal Examination (DRE). After these initial tests patients 
may be reassured that they do not have prostate cancer. Alternatively further 
testing can confirm a diagnosis of prostate cancer.
Further Diagnostic Tests
A Trans-Rectal Ultra Sound (TRUS) Biopsy will reveal if cancerous cells are 
present. If a diagnosis of prostate cancer is made, more tests to find out 
whether it has spread will be necessary e.g. CT, MRI and bone scans. 
Treatment Options for Prostate Cancer
Possible treatment options for prostate cancer include: external beam
radiotherapy -  where radiation is used to kill cancer cells; surgery -  where the
prostate gland is removed; hormone therapy -  where testosterone production is
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altered; brachytherapy -  where radioactive seeds are implanted into the 
prostate, or active monitoring where the state of the cancer is closely observed 
and treatment started if necessary.
Life After Treatment
All prostate cancer treatments involve varying degrees of medical intervention. 
These interventions range from four hours of major surgery under a general 
anaesthetic to regular check ups and PSA tests (active monitoring). Surgery, 
radiotherapy, brachytherapy and hormone therapy are all effective in the 
treatment of prostate cancer but have associated side effects. Side effects 
include: urinary incontinence, sexual dysfunction, bowel problems, hot flushes 
(Engstrom, 2005), breast swelling and tenderness, weight gain and 
osteoporosis. Certain side effects are only caused by one particular treatment 
e.g. breast swelling is commonly seen in men having hormone therapy to treat 
their prostate cancer. Urinary incontinence and sexual dysfunction are caused 
by all four of the treatments described above. Urinary incontinence can range 
from a few drops leaking out to total lack of control, and can be acute or 
chronic. Sexual dysfunction includes: loss of libido, infertility, erectile 
dysfunction, inability to orgasm, etc.
Sexual Dysfunction
Matthew et al. (2005) reviewed the literature related to sexual dysfunction 
following radical prostatectomy from 1966 to 2004. They found that several 
studies reported that 44% to 75% of men experienced sexual dysfunction, of 
whom more than 60% experienced distress because of their sexual dysfunction 
problems. This review highlighted the need for a broader perspective of sexual
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dysfunction emphasizing factors such as: perceptions of inadequacy, anxieties 
in regard to performance and depression in each member of the couple, overly 
enthusiastic expectations, partner’s physical and emotional readiness to resume 
active sex and the quality of the nonsexual relationship of the couple. This 
review also pointed out the need to explore the role of resumed satisfying 
sexuality in overall quality of life following treatment. Rosing and Berberich
(2004) also support the idea that sexual dysfunction has psychological and 
physical components. Tan, Waldman and Bostick (2002) found that cancer and 
its treatment often led to disruptions in family and social relationships, and that 
sexual relationships were most disrupted.
Once patients have been treated for prostate cancer they will be followed up for 
a number of years to monitor their physical progress. Weber and Sherwill- 
Navarro (2005) reviewed 30 years of research on the ‘psychosocial 
consequences’ of prostate cancer. They stated that ‘survivorship’ in prostate 
cancer patients is commonly complicated by long-term disease-specific side 
effects, such as; sexual and urinary dysfunction. Studies have shown that the 
psychological impact of prostate cancer continues long after the diagnosis and 
treatment phases have been completed. Baker, Denniston, Smith and West
(2005) used the Cancer Problems in Living Scale (CPILS) to assess 752 
patients, 97 of whom had prostate cancer. They found that a year on from 
diagnosis: 68% of patients were concerned about their illness returning, 58% 
had fears about the future, and 41% reported sexual dysfunction as a major 
concern. However, this study did not look at the association between the level 
of sexual dysfunction and psychological problems. The study also had
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methodological problems due to a low rate of consent to take part, resulting in 
limited generalizability of the findings.
Anxiety, Depression and Sexual Dysfunction
Many studies have reported that cancer and psychological problems, such as 
anxiety and depression, often co-occur (Tan, Waldman & Bostick, 2002). 
General theoretical psychological models of why people may experience 
anxiety and depression have been used in relation to cancer patients (Noyes et 
al., 1998; Massie et al., 1998). Models of Post-traumatic Stress Disorder have 
also been used to explain some of the psychological symptoms that people 
experience following a diagnosis of cancer and subsequent treatment (Smith et 
al., 1999).
Manzanera et al. (2003) assessed a sample of 54 patients with various types of 
cancer using the Hospital Anxiety and Depression Scale (HADS; Zigmond & 
Snaith, 1983). They found that 32% reported depressive disorders and 30% 
anxiety disorders. Kollner, Lautenschlager and Pajonk (2004) reported in their 
review paper that the frequency of co-occurrence is approximately 50% and that 
depression, anxiety and possibly post-traumatic stress disorder are the 
problems most relevant in prostate cancer. Hervouet et al. (2005) stated that 
few studies have evaluated the prevalence of anxiety and depression in 
prostate cancer patients. They assessed 861 patients with prostate cancer 
using HADS, the European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) and a supplementary Prostate 
Cancer-Specific Module (PCSM). Hervouet et al. (2005) found that sexual 
difficulties were most frequently reported (70.5%), with anxiety at 23.7% and
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depression at 17%. Roth et al. (1998) assessed 93 men with prostate cancer 
using the HADS, and found that 32.6% scored at or above the HADS anxiety 
cut-off and 15.2% scored at or above the depression cut-off. These studies did 
not examine the association between levels of sexual dysfunction and levels of 
anxiety and depression.
Bez et al. (2005) examined levels of anxiety and depression in prostate cancer 
patients with and without sexual dysfunction. They assessed 80 men using the 
HADS, the Short Form-36 Quality of Life Scale (SF-36) and the Arizona Sexual 
Experience Scale (ASEX; McGahuey et al., 2000). They reported that 69% of 
patients sampled did experience sexual dysfunction following treatment for 
prostate cancer. They also found that men with sexual dysfunction had higher 
levels of depression and a lower quality of life than men who did not have any 
sexual dysfunctions. No significant differences were found in levels of anxiety 
for prostate cancer patients with or without sexual dysfunction. This study has 
yet to be published and has not been peer reviewed; therefore, any findings 
must be treated with caution until full methodological details are available.
Other studies have reported certain factors that are associated with 
psychological distress when being diagnosed and treated for prostate cancer. 
Balderson and Towell (2003) assessed 94 men with various stages of prostate 
cancer using the HADS and the Functional Assessment of Cancer Therapy- 
Prostate Instrument (FACT-P). They found that 38% of patients scored at or 
above the HADS cut-off score for anxiety and depression. They also reported 
that a multivariate regression analysis revealed that social well being, physical 
well-being and functional well-being were significant inverse predictors of
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psychological distress. They recommended that Health Professionals should 
be aware of the potential for psychological distress in patients exhibiting poor 
physical functioning and those with apparent deficits in social or family support. 
This study did not look at sexual function alone, but instead as part of a more 
general ‘health related quality of life’ measure, which considered a number of 
physical factors. Balderson and Towell (2003) recommended that future studies 
may find useful information by looking at certain dimensions of ‘health related 
quality of life’ in isolation, sexual function being one of these dimensions.
Schnoll, Knowles and Harlow (2002) looked at the psychosocial, clinical and 
demographic correlates of adjustment to cancer. Positive psychosocial factors 
included: higher levels of social support, optimism, meaning in life, and lower 
levels of avoidant-type coping. They found that positive clinical and 
demographic factors included; being married, higher income, higher level of 
education and a positive perception of their own health. One way of assessing 
perception of health would be to use the Illness Perception Questionnaire - 
Revised (Moss-Morris et al., 2002), which has been used with cancer patients 
(Scharloo et al., 2005). Scharloo et al. (2005) found that illness perceptions 
were significantly related to quality of life; patients who perceived themselves to 
have better health had better quality of life. None of these studies examined 
factors associated with psychological distress in the context of sexual 
dysfunction.
Roesch et al. (2005) reviewed 33 studies, a total of 3133 men with prostate 
cancer, to assess the relationship between coping style and adjustment. They 
found that men with prostate cancer who used approach, problem-focused, and
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emotion-focused coping were healthier psychologically and physically. 
However, Men with prostate cancer who used avoidance type coping 
experienced more negative psychological adjustment and worse physical 
health. Mehta, Lubeck, Pasta and Litwin (2003) assessed 519 men with 
prostate cancer from the CaPSURE (Cancer of the Prostate Strategic Urologic 
Research Endeavour) registry. They used the RAND 36 item Health Survey 
and the UCLA Prostate Cancer Index to look at health related quality of life. 
Following a multivariate linear regression analysis they found that there was an 
association between general health, mental health and fear of cancer 
recurrence; patients with good general and mental health were less fearful.
The need for a better understanding of patient’s psychological needs at various 
stages has been highlighted (e.g. Matthew et al., 2005). Bez et al. (2005) 
proposed that further investigation into the psychological aspects of sexual 
dysfunction in prostate cancer patients is necessary in order to meet patient 
needs. As yet no study has examined the association between level of sexual 
dysfunction and levels of anxiety and depression. This study would add to 
previous knowledge regarding the psychological needs of men following 
treatment for prostate cancer. This in turn may assist the decisions made 
regarding the provision of psychological services for prostate cancer patients.
In addition, looking at other factors associated with psychological distress in 
prostate cancer patients experiencing sexual dysfunction may assist clinicians 
in identifying patients who may be more ‘at risk’ of high levels of anxiety and 
depression, and allow them to intervene at an early stage in the treatment 
process.
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Aims & Hypotheses
i) Aims
This study aims to investigate levels of anxiety, depression and sexual 
dysfunction in men following various treatments for prostate cancer. The 
primary objectives of this study are to:
- Assess the self-reported level of sexual dysfunction,
- Assess the self-reported level of anxiety,
- Assess the self-reported level of depression,
- Examine any relationship between level of sexual dysfunction and 
levels of anxiety and depression.
The secondary objectives are to:
- Identify coping style,
- Assess ‘Illness perceptions’,
- Assess ‘Health Related Quality of Life’,
- Examine the relationship between coping style and perception of
illness and the level of sexual dysfunction and levels of anxiety 
and depression.
- Examine the relationship between health related quality of life and 
level of sexual dysfunction and levels of anxiety and depression.
ii) Hypotheses
It is hypothesized that levels of anxiety and depression will be related to the 
level of sexual dysfunction. The dependent variables in this study will be: level 
of anxiety and level of depression. Independent variables that will be
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investigated include: level of sexual dysfunction, coping style, illness 
perceptions; and ‘Health Related Quality of Life’.
Following various studies and reviews of the literature (Matthew et al. 2005; 
Hervouet et al., 2005; Bez et al., 2005) it is predicted that:
1) Men with higher levels of sexual dysfunction will report higher levels of 
anxiety and depression.
Schnoll, Knowles and Harlow (2002) reported an association between lower 
levels of avoidant type coping and a positive adjustment to cancer. Roesch et 
al. (2005) reviewed the literature and concluded that men who used avoidance 
type coping experienced worse psychological and physical health. Therefore, it 
is predicted that:
2) Men who have lower levels of avoidance type coping with have lower 
levels of anxiety and depression.
Following the work of Schnoll, Knowles and Harlow (2002), who found that men 
with a positive perception of their own health had a more positive adjustment to 
cancer, it is predicted that:
3) Men who perceive themselves to have higher levels of illness will have 
higher levels of anxiety and depression.
Mehta, Lubeck, Pasta and Litwin (2003) found that there was an association 
between general health, mental health and fear of cancer recurrence; patients 
with good general and mental health were less fearful. Therefore, it is 
hypothesised that:
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4) Men who report higher levels of ‘health related quality of life’ will have lower 
levels of anxiety and depression.
Plan of Investigation
i) Participants
Participants will be recruited from patients attending Urology or Urooncology 
out-patient clinics in North Glasgow. More specifically, participants will be 
patients who are being followed-up after being diagnosed with and treated for 
prostate cancer.
ii) Recruitment
Permission has been given by the Urology and Urooncology Services to recruit 
patients attending Urology and Urooncology clinics on an outpatient basis. 
Patient information sheets, two consent forms and five questionnaires will be 
put into sealed envelopes by the Chief Investigator. These envelopes will then 
be given out by Clinical Nurse Specialists to patients who attend Urology or 
Urooncology out-patient clinics in North Glasgow. Patients who would like to 
participate will then be able to complete the questionnaires in their own time 
and return them by post to the Chief Investigator at the Section of Psychological 
Medicine, Gartnavel Hospital.
iii) Measures 
Anxiety and Depression
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) is 
a 14-item self-report scale, which is made up of two 7-item subscales that 
measure anxiety and depression. People are asked to rate each item on a 3
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point scale, ranging from the absence of a symptom (0), to the maximum 
symptoms (3); therefore the higher the score, the higher the anxiety or 
depression. Reliability coefficients for the sub-scales on the HADS (Cronbach’s 
alpha) were 0.76 for the anxiety sub-scale and 0.60 for the depression sub­
scale, indicating satisfactory internal reliability (Zigmond & Snaith, 1983).
Quality of Life
The RAND SF-36 v2 plus the UCLA Prostate Cancer Index will be used to 
assess ‘Health Related Quality of Life’.
The RAND 36-Item Health Survey (Hays et al., 1993) assesses ‘Health Related 
Quality Of Life’ in eight domains, namely: Physical functioning, role limitations 
due to physical health problems, role limitations due to emotional problems, 
vitality, mental health, social functioning, bodily pain, general health and health 
transition.
The UCLA Prostate Cancer Index (Litwin et al., 1998) assesses disease- 
specific ‘Health Related Quality Of Life’ in six domains that are of particular 
relevance to men treated for prostate cancer. The six domains are: Urinary 
function, bowel function, sexual function, urinary bother, bowel bother and 
sexual bother.
Sexual Dysfunction
The Arizona Sexual Experiences Scale (ASEX) will be used to assess level of 
sexual dysfunction (McGahuey et al., 2000). The ASEX is a five item self-report 
scale that quantifies: sex drive, arousal, penile erection, ability to reach orgasm,
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and satisfaction from orgasm. Each of these items is measured on a 6 point 
Likert scale, ranging from 1 ‘hyperfunction’ to 6 ‘hypofunction’. Total scores can 
range from 5 to 30, with higher scores indicating a higher level of sexual 
dysfunction.
For the purposes of this study patients who have a total score of 19 or more, 
score a 5 or 6 on any one item, or score a 4 or more on any three items, will be 
regarded as having sexual dysfunction (McGahuey et al., 2000). Satisfactory 
psychometric properties of the ASEX have been described by McGahuey et al. 
(2000), internal reliability was good (Cronbach’s alpha = 0.9055).
Coping Style
Coping style data will be collected using the Brief COPE-B (Carver, 1997). The 
COPE-B has 14 subscales: active coping, planning, positive reframing, 
acceptance, humour, religion, using emotional support, using instrumental 
support, self-distraction, denial, venting, substance abuse, behavioural 
disengagement, self-blame. Each of these subscales has two parts, making a 
total of 28 items. These items are rated from 0 ‘I haven’t been doing this at all’, 
to 3 ‘I’ve been doing this a lot’. The subscales on the COPE-B can then be 
grouped to give three different coping styles; problem-focussed, emotion- 
focussed, and dysfunctional coping (Carver et al., 1989; Coolidge et al., 2000). 
Reliability coefficients for the sub-scales (Cronbach’s alpha) ranged from 0.50 
to 0.90, indicating satisfactory internal reliability (Carver, 1997).
Illness Perception Questionnaire
The Illness Perception Questionnaire-Revised (Moss-Morris et al., 2002) is a 
measure of patients’ cognitive and emotional representations of their illness.
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The first part of the questionnaire measures the illness identity dimension with a 
list of 14 commonly occurring prostate-specific symptoms. Patients are asked to 
rate if they have experienced each symptom since their illness and if they 
believe the symptom to be specifically related to their illness (yes or no). The 
yes-rated items form the illness identity scale; with higher scores indicating a 
stronger belief that the symptoms are part of the patient’s illness.
The second part of the IPQ-R consists of 38 statements using 5-point Likert 
scales; ranging from ‘strongly agree’ to ‘strongly disagree’. It provides separate 
scores for the consequences, timeline, control, illness coherence, and 
emotional representations scales. High scores indicate stronger beliefs in 
serious consequences of the disease, a chronic long-term disease, illness 
and/or symptoms as cyclical in nature, the patients’ own ability to control 
symptoms, and the effectiveness of treatment in controlling the illness. Higher 
scores on the illness coherence scale indicate a higher degree to which patients 
believe they have a coherent model of the illness, and higher scores on the 
emotional representations scale indicate a stronger emotional response to 
illness. The third part, questions about causal attributions, uses the same 5- 
point scale and consists of 18 items. Higher scores indicate stronger beliefs in 
own behaviour, chance, or aging causing the illness. Reliability coefficients for 
the sub-scales (Cronbach’s alpha) ranged from 0.70 to 0.90, indicating 
satisfactory internal reliability (Moss-Morris, 2002).
iv) Design & Procedures 
The study will use a cross sectional design. Data will be collected for a single 
time point for each participant. The study will use a range of measures to
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gather information, namely; HADS, RAND plus UCLA-PCI, ASEX, COPE-B and 
IPQ-R. These measures are all self-report, and will record participants’ 
perceptions of: their symptoms of anxiety and depression, their health related 
quality of life, their coping, their illness, and their sexual functioning. The 
associations between these variables will then be examined to allow greater 
understanding of the factors that contribute to psychological morbidity.
Patients will be given a sealed pack when they attend the Urology or 
Urooncology outpatient clinics in North Glasgow. Each pack will contain: a 
detailed patient information sheet explaining the purpose of the study and what 
will be involved, two consent forms, and five questionnaires (HADS, RAND plus 
UCLA-PCI, ASEX, COPE-B and IPQ-R). Patients will be asked to put their 
hospital number rather than their name on top of all questionnaires.
Participants who choose to complete the questionnaires will then post them 
back to the Chief Investigator at the Section of Psychological Medicine, 
Gartnavel Royal Hospital in a freepost envelope, which will be included in the 
pack. Patients will be asked to complete two consent forms these will then be 
sealed in a separate envelope and held by the Academic Supervisor (Professor 
Keith Millar). Professor Millar will countersign both consent forms, one will be 
held on file and the other will be sent back to the patient for their reference. As 
suggested in COREC 'Guidelines for Researchers -  Information Sheets & 
Consent Forms' (Version 2.0 22 November 2005); "If the consent form is to be 
signed at home and returned by mail to the researcher, 2 copies must be 
provided, both to be returned and countersigned by the researcher, and one 
copy posted back to the participant".
77
v) Settings & Equipment
All participant correspondence will take place through Urology and Urooncology 
clinics, in North Glasgow.
vi) Power Calculation
This study will investigate two dependent variables, namely; level of anxiety and 
level of depression. Four independent variables will be investigated; level of 
sexual dysfunction, coping style, perception of illness, and health related quality 
of life.
According to one formula provided by Green (1991), N = 50 + 8m, where m is 
the number of independent variables. Therefore, for this study N = 50 + (8 x 4), 
which is 82. In line with convention the level of significance is 0.05 and power is 
0.80 (Cohen, 1992). This figure is similar to the number of participants used in 
previous studies in this area (Balderson & Towell, 2003; Bez et al., 2005).
vii) Data Analysis
Data will be analysed using SPSS version 12.0.1 for windows. Initially, 
summary statistics will be used to describe the sample in terms of levels of 
anxiety, depression, and sexual dysfunction; and also coping style, illness 
perception, and health related quality of life. Correlational analyses will also be 
required to investigate the relationships between variables. Scores for anxiety 
and depression will be analysed both as a continuous measure and according 
to established cut-off points for degrees of caseness on the HADS (Zigmond & 
Snaith, 1994). Zigmond & Snaith (1994) recommended that, for the anxiety and 
depression scales, raw scores of between 8 and 10 identify mild cases, 11-15
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moderate cases, and 16 or above severe cases. Finally, a regression analysis 
will be carried out with the HADS score as the outcome measure.
Practical Applications
Studies have identified that the psychological needs of prostate cancer patients 
are often unmet (Lintz et al., 2003). It has also been reported that sexual 
dysfunction is the most commonly reported side-effect of treatment for prostate 
cancer (Herouvet et al. 2005). Studies support the idea that sexual dysfunction 
has both physical and psychological components (Rosing & Berberich, 2004), 
but currently most treatments options for sexual dysfunction are of a physical 
nature and are not very successful (Matthew et al., 2005). A better 
understanding of levels of anxiety, depression and sexual dysfunction in men 
with prostate cancer would add to existing information regarding the 
psychological components that are associated with sexual difficulties. This in 
turn would help to guide psychological treatment options for men with sexual 
dysfunction following treatment for prostate cancer. Looking at other factors 
associated with psychological distress in prostate cancer patients such as; 
coping style, illness perception, and quality of life, may assist clinicians in 
identifying patients who may be more ‘at risk’ of high levels of anxiety and 
depression, and allow them to intervene at an early stage in the treatment 
process.
Timescale
Data collection -  January 2007 to May 2007 
Write up -  May 2007 to July 2007
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Ethical Approval
Ethical approval will be sought from Greater Glasgow Health Board at the 
Glasgow West Local Research Ethics Committee meeting in December 2006.
The proposal was submitted to the In-House Trials Advisory Board (IHTAB) 
meeting at the Beatson Oncology Centre on 14th November 2006 (see 
Appendix 3.1). The project has approval from this panel to proceed to the 
Glasgow West Local Research Ethics Committee.
One particular ethical issue to consider is the onward referral pathway for 
patients who are found to have clinically significant levels of anxiety and 
depression. This will be clearly established and agreed with the Clinical 
Psychologists at the Beatson Oncology Centre. Participants who have 
completed questionnaires will have included their hospital number; this would 
allow the Chief Investigator to contact the Consultant Clinical Oncologist, 
Consultant Urologist or Clinical Nurse Specialist. The patient could then be 
offered the opportunity to see a Clinical Psychologist at the Beatson Oncology 
Centre if they wished to.
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Title
Life After Treatment for Prostate Cancer: Levels of Anxiety, Depression, and 
Sexual Dysfunction.
Abstract
This study aimed to assess levels of anxiety, depression and sexual dysfunction 
in men following treatment for prostate cancer. It was hypothesised that men 
with higher levels of sexual dysfunction would report higher levels of anxiety 
and depression. The study also aimed to examine how coping, quality of life, 
and perception of illness were related to each other and to levels of anxiety, 
depression, and sexual dysfunction. Fifty-two participants were recruited from 
patients attending Urology or Uro-oncology out-patient clinics in North Glasgow. 
Data were collected for a single time point for each participant using six self- 
report measures, namely; the Hospital Anxiety and Depression Scale (HADS), 
the RAND SF-36 v2 plus the UCLA Prostate Cancer Index (UCLA-PCI), the 
Arizona Sexual Experiences Scale (ASEX), the Brief COPE questionnaire 
(COPE-B) and the Illness Perception Questionnaire-Revised (IPQ-R). Data 
were examined using correlation analyses. Significant correlations were 
discovered between levels of depression and levels of sexual dysfunction. 
Significant correlations were also found between depression scores on the 
HADS, specific dimensions on the COPE-B and IPQ-R, and all dimensions of 
health-related quality of life assessed using the SF-36. Limitations of the study, 
possible clinical applications and ideas for future research are discussed.
Keywords -  Prostate, cancer, anxiety, depression, sexual dysfunction.
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Introduction
Symptoms, Diagnosis and Treatment of Prostate Cancer 
Prostate cancer is one of the most common cancers, affecting approximately 
30,900 men every year in the United Kingdom [1]. Men who have prostate 
cancer may experience: problems urinating, pain in genitals and upon 
ejaculation, erection difficulties, pain in the lower back and in hips or pelvis, and 
blood in the urine. If prostate cancer is suspected a number of tests are 
required before this diagnosis can be confirmed, including PSA tests, CT, MRI 
and bone scans. If a diagnosis of prostate cancer is confirmed possible 
treatment options include: external beam radiotherapy, surgery -  where the 
prostate gland is removed; hormone therapy, brachytherapy -  where 
radioactive seeds are implanted into the prostate, or active monitoring where 
the state of the cancer is closely observed and treatment started if necessary.
Life After Treatment
All prostate cancer treatments involve varying degrees of medical intervention. 
These interventions range from four hours of major surgery under a general 
anaesthetic to regular check ups and PSA tests (active monitoring). Surgery, 
radiotherapy, brachytherapy and hormone therapy are all effective in the 
treatment of prostate cancer but have associated side effects. Side effects 
include: urinary incontinence, sexual dysfunction, bowel problems, hot flushes, 
breast swelling and tenderness, weight gain and osteoporosis. Certain side 
effects, such as urinary incontinence and sexual dysfunction, are caused by all 
four of the treatments described above. Urinary incontinence can range from a 
few drops leaking out to total lack of control, and can be acute or chronic.
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Sexual dysfunction can include; loss of libido, infertility, erectile dysfunction, and 
inability to orgasm.
Sexual Dysfunction
Matthew et al. [2] reviewed the literature related to sexual dysfunction following 
radical prostatectomy from 1966 to 2004. They found that several studies 
reported that 44% to 75% of men experienced sexual dysfunction, of whom 
more than 60% experienced distress because of their sexual dysfunction 
problems. This review highlighted the need for a broader perspective of sexual 
dysfunction emphasizing factors such as: perceptions of inadequacy, anxieties 
in regard to performance and depression in each member of the couple, overly 
enthusiastic expectations, partner’s physical and emotional readiness to resume 
active sex and the quality of the nonsexual relationship of the couple. This 
review also pointed out the need to explore the role of resumed satisfying 
sexuality in overall quality of life following treatment. Rosing and Berberich [3] 
also support the idea that sexual dysfunction has psychological and physical 
components. Tan, Waldman and Bostick [4] found that cancer and its treatment 
often led to disruptions in family and social relationships, and that sexual 
relationships were most disrupted.
Once patients have been treated for prostate cancer they will be followed up for 
a number of years to monitor their physical progress. Weber and Sherwill- 
Navarro [5] reviewed 30 years of research on the ‘psychosocial consequences’ 
of prostate cancer. They stated that ‘survivorship’ in prostate cancer patients is 
commonly complicated by long-term disease-specific side effects, such as; 
sexual and urinary dysfunction. Studies have shown that the psychological
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impact of prostate cancer continues long after the diagnosis and treatment 
phases have been completed. Baker, Denniston, Smith and West [6] used the 
Cancer Problems in Living Scale (CPILS) to assess 752 patients, 97 of whom 
had prostate cancer. They found that a year on from diagnosis: 68% of patients 
were concerned about their illness returning, 58% had fears about the future, 
and 41% reported sexual dysfunction as a major concern. However, this study 
did not look at the association between the level of sexual dysfunction and 
psychological problems. The study also had methodological problems due to a 
low rate of consent to take part, resulting in limited generalizability of the 
findings.
Anxiety, Depression and Sexual Dysfunction
Many studies have reported that cancer and psychological problems, such as 
anxiety and depression, often co-occur [4]. General theoretical psychological 
models of why people may experience anxiety and depression have been used 
in relation to cancer patients [7, 8]. Models of Post-traumatic Stress Disorder 
have also been used to explain some of the psychological symptoms that 
people experience following a diagnosis of cancer and subsequent treatment
[9].
Manzanera et al. [10] assessed a sample of 54 patients with various types of 
cancer using the Hospital Anxiety and Depression Scale [11]. They found that 
32% reported depressive disorders and 30% anxiety disorders. Kollner, 
Lautenschlager and Pajonk [12] reported in their review paper that the 
frequency of co-occurrence is approximately 50% and that depression, anxiety 
and possibly post-traumatic stress disorder are the problems most relevant in
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prostate cancer. Hervouet et al. [13] stated that few studies have evaluated the 
prevalence of anxiety and depression in prostate cancer patients. They 
assessed 861 patients with prostate cancer using HADS, the European 
Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30) and a supplementary Prostate Cancer- 
Specific Module (PCSM). Hervouet et al. [13] found that sexual difficulties were 
most frequently reported (70.5%), with anxiety at 23.7% and depression at 17%. 
Roth et al. [14] assessed 93 men with prostate cancer using the HADS, and 
found that 32.6% scored at or above the HADS anxiety cut-off and 15.2% 
scored at or above the depression cut-off. These studies did not examine the 
association between levels of sexual dysfunction and levels of anxiety and 
depression.
Bez et al. [15] examined levels of anxiety and depression in prostate cancer 
patients with and without sexual dysfunction. They assessed 80 men using the 
HADS, the Short Form-36 Quality of Life Scale (SF-36) and the Arizona Sexual 
Experience Scale [16]. They reported that 69% of patients sampled did 
experience sexual dysfunction following treatment for prostate cancer. They 
also found that men with sexual dysfunction had higher levels of depression and 
a lower quality of life than men who did not have any sexual dysfunctions. No 
significant differences were found in levels of anxiety for prostate cancer 
patients with or without sexual dysfunction. This study has yet to be published 
and has not been peer reviewed; therefore, any findings must be treated with 
caution until full methodological details are available.
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Other studies have reported certain factors that are associated with 
psychological distress when being diagnosed and treated for prostate cancer. 
Balderson and Towell [17] assessed 94 men with various stages of prostate 
cancer using the HADS and the Functional Assessment of Cancer Therapy- 
Prostate Instrument (FACT-P). They found that 38% of patients scored at or 
above the HADS cut-off score for anxiety and depression. They also reported 
that a multivariate regression analysis revealed that social well being, physical 
well-being and functional well-being were significant inverse predictors of 
psychological distress. They recommended that Health Professionals should 
be aware of the potential for psychological distress in patients exhibiting poor 
physical functioning and those with apparent deficits in social or family support. 
This study did not look at sexual function alone, but instead as part of a more 
general ‘health related quality of life’ measure, which considered a number of 
physical factors. Balderson and Towell [17] recommended that future studies 
may find useful information by looking at certain dimensions of ‘health related 
quality of life’ in isolation, sexual function being one of these dimensions.
Schnoll, Knowles and Harlow [18] looked at the psychosocial, clinical and 
demographic correlates of adjustment to cancer. Positive psychosocial factors 
included: higher levels of social support, optimism, meaning in life, and lower 
levels of avoidant-type coping. They found that positive clinical and 
demographic factors included; being married, higher income, higher level of 
education and a positive perception of their own health. One way of assessing 
perception of health would be to use the Illness Perception Questionnaire - 
Revised [19], which has been used with cancer patients [20]. Scharloo et al. 
[20] found that illness perceptions were significantly related to quality of life;
patients who perceived themselves to have better health had better quality of 
life. None of these studies examined factors associated with psychological 
distress in the context of sexual dysfunction.
Roesch et al. [21] reviewed 33 studies, a total of 3133 men with prostate 
cancer, to assess the relationship between coping style and adjustment. They 
found that men with prostate cancer who used approach, problem-focused, and 
emotion-focused coping were healthier psychologically and physically.
However, men with prostate cancer who used avoidance type coping 
experienced more negative psychological adjustment and worse physical 
health. Mehta, Lubeck, Pasta and Litwin [22] assessed 519 men with prostate 
cancer from the CaPSURE (Cancer of the Prostate Strategic Urologic Research 
Endeavour) registry. They used the RAND 36 item Health Survey and the 
UCLA Prostate Cancer Index to look at health related quality of life. Following a 
multivariate linear regression analysis they found that there was an association 
between general health, mental health and fear of cancer recurrence; patients 
with good general and mental health were less fearful.
The need for a better understanding of patient’s psychological needs at various 
stages has been highlighted [2], Bez et al. [15] proposed that further 
investigation into the psychological aspects of sexual dysfunction in prostate 
cancer patients is necessary in order to meet patient needs. As yet no study 
has examined the association between level of sexual dysfunction and levels of 
anxiety and depression. This study would add to previous knowledge regarding 
the psychological needs of men following treatment for prostate cancer. This in 
turn may assist the decisions made regarding the provision of psychological
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services for prostate cancer patients. In addition, looking at other factors 
associated with psychological distress in prostate cancer patients experiencing 
sexual dysfunction may assist clinicians in identifying patients who may be more 
‘at risk’ of high levels of anxiety and depression, and allow them to intervene at 
an early stage in the treatment process.
The aims of the current study were to investigate levels of self-reported anxiety, 
depression and sexual dysfunction in men following various treatments for 
prostate cancer. The study also aimed to examine any relationship between 
level of sexual dysfunction and levels of anxiety and depression. Secondary 
objectives were to assess coping, illness perceptions and health related quality 
of life, and to explore any relationships between these factors and levels of 
anxiety, depression and sexual dysfunction. It was hypothesized that men with 
higher levels of sexual dysfunction would report higher levels of anxiety and 
depression. It was also predicted that men who had lower levels of avoidance 
type coping would have lower levels of anxiety and depression, and that men 
who perceived themselves to have higher levels of illness would have higher 
levels of anxiety and depression. Finally it was hypothesised that men who 
reported higher levels of ‘health related quality of life’ would have lower levels of 
anxiety and depression.
Method
Fifty-two participants were recruited from patients attending Urology or Uro- 
oncology out-patient clinics in North Glasgow. Inclusion criteria stated that 
participants must be aged 16 years or older, and have received a diagnosis of 
prostate cancer and received treatment. Participants were recruited from those
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who are 'relatively stable, follow-up' cases. 'Relatively stable' was defined as at 
least 3 months post diagnosis and initial treatment. Patients who could not 
understand written English were excluded from the study due to the self-report 
design of the questionnaires. Patients who were suffering from any other life- 
threatening illnesses were also excluded due to the high levels of distress this 
may cause. Ethical approval was obtained from the Glasgow West Local 
Research Ethics Committee meeting in February 2007 (see Appendix 4.1).
Questionnaire packs were compiled by the Chief Investigator and distributed by 
Clinical Nurse Specialists at Urology or Uro-oncology outpatient clinics.
Patients were given sealed packs containing: a detailed patient information 
sheet explaining the purpose of the study and what would be involved 
(Appendix 4.2), two consent forms (Appendix 4.3), and five questionnaires 
(Appendix 4.4). Patients were asked to put their hospital number rather than 
their name on top of all questionnaires. Participants who chose to complete the 
questionnaires then posted them back to the Chief Investigator in a freepost 
envelope, which was included in the pack. Patients were asked to complete 
two consent forms and seal them in a separate envelope. A second member of 
the research team countersigned both consent forms, one was held on file and 
the other was be sent back to the patient for their reference with a standard 
letter thanking them for their participation (Appendix 4.5). As suggested in 
COREC 'Guidelines for Researchers -  Information Sheets & Consent Forms' 
(Version 2.0 22 November 2005); "If the consent form is to be signed at home 
and returned by mail to the researcher, two copies must be provided, both to be 
returned and countersigned by the researcher, and one copy posted back to the 
participant”.
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M easures
The Hospital Anxiety and Depression Scale [11] is a 14-item self-report scale, 
which is made up of two 7-item subscales that measure anxiety and depression. 
Reliability coefficients for the sub-scales on the HADS (Cronbach’s alpha) were 
0.76 for the anxiety sub-scale and 0.60 for the depression sub-scale, indicating 
satisfactory internal reliability [11].
The RAND SF-36 v2 plus the UCLA Prostate Cancer Index was used to assess 
‘Health Related Quality of Life’. The RAND 36-Item Health Survey [23] 
assesses ‘Health Related Quality Of Life’ in nine domains, namely: Physical 
functioning, role limitations due to physical health problems, role limitations due 
to emotional problems, vitality, mental health, social functioning, bodily pain, 
general health and health transition. Demographic information including; age, 
ethnic background, relationship status, education, employment, was also 
collected using the questionnaire.
The UCLA Prostate Cancer Index [24] assesses disease-specific ‘Health 
Related Quality Of Life’ in six domains that are of particular relevance to men 
treated for prostate cancer. The six domains are: Urinary function, bowel 
function, sexual function, urinary bother, bowel bother and sexual bother.
The Arizona Sexual Experiences Scale (ASEX) was used to assess level of 
sexual dysfunction [16]. The ASEX is a five item self-report scale that 
quantifies: sex drive, arousal, penile erection, ability to reach orgasm, and 
satisfaction from orgasm (see Appendix 4.4). Each of these items is measured
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on a 6 point Likert scale, ranging from 1 ‘hyperfunction’ to 6 ‘hypofunction’.
Total scores can range from 5 to 30, with higher scores indicating a higher level 
of sexual dysfunction. Satisfactory psychometric properties of the ASEX have 
been described by McGahuey et al. [16], internal reliability was good 
(Cronbach’s alpha = 0.9055).
Coping style data was collected using the Brief COPE-B [25]. The COPE-B has 
14 subscales: active coping, planning, positive reframing, acceptance, humour, 
religion, using emotional support, using instrumental support, self-distraction, 
denial, venting, substance abuse, behavioural disengagement, self-blame.
Each of these subscales has two parts, making a total of 28 items. These items 
are rated from 0 ‘I haven’t been doing this at all’, to 3 I ’ve been doing this a lot’. 
Reliability coefficients for the sub-scales (Cronbach’s alpha) ranged from 0.50 
to 0.90, indicating satisfactory internal reliability [26].
The Illness Perception Questionnaire-Revised [19] is a measure of patients’ 
cognitive and emotional representations of their illness. The first part of the 
questionnaire measures the illness identity dimension with a list of 14 commonly 
occurring prostate-specific symptoms. Patients are asked to rate if they have 
experienced each symptom since their illness and if they believe the symptom 
to be specifically related to their illness (yes or no). The yes-rated items form 
the illness identity scale; with higher scores indicating a stronger belief that the 
symptoms are part of the patient’s illness.
The second part of the IPQ-R consists of 38 statements using 5-point Likert 
scales; ranging from ‘strongly agree’ to ‘strongly disagree’. It provides separate
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scores for the consequences, timeline, control, illness coherence, and 
emotional representations scales. High scores indicate stronger beliefs in 
serious consequences of the disease, a chronic long-term disease, illness 
and/or symptoms as cyclical in nature, the patients’ own ability to control 
symptoms, and the effectiveness of treatment in controlling the illness. Higher 
scores on the illness coherence scale indicate a higher degree to which patients 
believe they have a coherent model of the illness, and higher scores on the 
emotional representations scale indicate a stronger emotional response to 
illness. The third part, questions about causal attributions, uses the same 5- 
point scale and consists of 18 items. Higher scores indicate stronger beliefs in 
own behaviour, chance, or aging causing the illness. Reliability coefficients for 
the sub-scales (Cronbach’s alpha) ranged from 0.70 to 0.90, indicating 
satisfactory internal reliability [19].
Design & Procedures
The study used a cross sectional design. Data were collected for a single time 
point for each participant. The study used a range of measures to gather 
information, namely; HADS, RAND plus UCLA-PCI, ASEX, COPE-B and IPQ-R. 
These measures are all self-report and recorded participants’ perceptions of: 
their symptoms of anxiety and depression, their health related quality of life, 
their coping, their illness, and their sexual functioning. The associations 
between these variables were then examined to allow greater understanding of 
the factors that contribute to psychological morbidity.
The study investigated two dependent variables, namely; level of anxiety and 
level of depression as assessed by the HADS. Four independent variables
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were investigated; level of sexual dysfunction, coping style, perception of 
illness, and health related quality of life. According to one formula provided by 
Green [27], N (the required sample size) = 50 + 8m, where m is the number of 
independent variables. Therefore, for this study N = 50 + (8 x 4), which is 82.
In line with convention the level of significance is 0.05 and power is 0.80 [28]. 
This figure is similar to the number of participants used in previous studies in 
this area [17, 15].
Data Analysis
Data were analysed using SPSS version 14.0.1 for windows. Initially, summary 
statistics were used to describe the sample in terms of demographic 
information, levels of anxiety, depression, and sexual dysfunction; and also 
coping style, illness perception, and health related quality of life. Correlational 
analyses were also required to investigate any relationships between variables. 
Scores for anxiety and depression were analysed both as a continuous 
measure and according to established cut-off points for degrees of caseness on 
the HADS [29]. Zigmond & Snaith [29] recommended that, for the anxiety and 
depression scales, raw scores of between 8 and 10 identify mild cases, 11-15 
moderate cases, and 16 or above severe cases. Caseness on the HADS 
anxiety and depression subscales, and levels of sexual dysfunction were also 
investigated for three age ranges: 55 to 65, 66 to 75, 76 or over. A regression 
analysis was also planned to further investigate any associations between 
HADS scores, sexual dysfunction, coping, illness perceptions and health-related 
quality of life.
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Results
One hundred and fifty questionnaire packs were distributed by Clinical Nurse 
Specialists at Urology or Uro-oncology outpatient clinics. Fifty-five completed 
packs were returned to the Chief Investigator, a 36.7% return rate. Three 
patients were excluded; two patients did not consent to take part in the study 
and one patient did not return the consent forms. Fifty-two patients were 
included in the study.
Patient Demographics
The demographic characteristics of the 52 patients are illustrated in Table 1.
The sample is described in terms of age, ethnic background, relationship status, 
education, and employment status.
[Insert Table 1 here]
Descriptive statistics, including mean scores, standard deviations and ranges 
for all outcome measures, are illustrated in Table 2.
[Insert Table 2 here]
Anxiety, Depression and Sexual Dysfunction
The mean score on the HADS anxiety subscale was 5.23 (SD 4.32). Seventy- 
six point nine percent of patients scored below clinically significant levels for 
anxiety on the HADS [29]. Seven point seven percent scored between 8 and 10 
(mild), 11.5% scored between 11 and 15 (moderate), and 3.9% scored 16 or 
more (severe). The mean score on the HADS depression subscale was 3.50 
(SD 3.39). Eighty-eight point four percent of patients scored below clinically 
significant levels for depression on the HADS. Seven point seven percent
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scored between 8 and 10 (mild), 3.9% scored between 11 and 15 (moderate), 
and none of the sample scored 16 or more (severe). The mean score on the 
ASEX was 24.21 out of 30 (SD 5.65), with higher scores indicating higher levels 
of sexual dysfunction. Mean scores on the UCLA PCI were 20.14 (SD 24.59) 
out of 100 for sexual function and 46.63 (SD 40.53) for sexual bother, with lower 
scores indicating lower levels of functioning.
Initially, correlation analyses were carried out to address the main research 
hypothesis; that men with higher levels of sexual dysfunction would report 
higher levels of anxiety and depression. These analyses aimed to examine any 
relationships between the main independent and dependent variables, namely, 
HADS anxiety and depression scores, and sexual dysfunction assessed using 
the ASEX and the UCLA PCI (sexual function and sexual bother). A significant 
positive correlation was found between HADS depression scores and ASEX 
scores (r=0.326, p<0.05); higher levels of depression were related to higher 
levels of sexual dysfunction. A significant negative correlation was discovered 
between HADS depression scores and UCLA PCI sexual function scores (r= - 
0.330, p<0.05), with higher levels of depression being related to lower levels of 
sexual functioning. No significant correlations (Pearson correlation, two-tailed) 
were found between HADS anxiety scores and the three measures of sexual 
dysfunction, or between HADS depression scores and UCLA PCI sexual bother 
scores.
For the 88.4% of patients who scored below clinically significant levels on the 
HADS depression subscale (7 or less), the mean ASEX score was 23.91 (SD 
5.7), and the mean UCLA PCI sexual function score was 21.86 (SD 25.40).
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Eleven point six percent of patients scored above clinically significant levels of 
depression (8 or more) on the HADS, the mean ASEX score for these patients 
was 26.5 (SD 5.05) and the mean sexual function score was 6.94 (SD 11.24).
Coping, Illness Perceptions, and Health Related Quality of Life 
Following on from the main research hypothesis further correlations were 
carried out in order to establish the nature of any relationships between HADS 
depression scores and coping, illness perceptions, and health related quality of 
life. Mean scores, standard deviations and ranges for these measures are 
illustrated in Table 2. Firstly, three dimensions of the COPE-B were found to be 
significantly correlated with HADS depression scores. The ‘denial’ dimension of 
the COPE-B was found to be positively correlated with HADS depression 
scores (r=0.369, p<0.01), with higher levels of denial being related to higher 
depression scores. The ‘substance use’ dimension of the COPE-B was found 
to be positively correlated (r=0.316, p<0.05), with higher levels of substance use 
being related to higher depression scores on the HADS. The ‘venting’ 
dimension of the COPE-B was also found to be positively correlated with HADS 
depression scores (r=0.486, p<0.01), with higher levels of venting being related 
to higher depression scores on the HADS.
The relationships between HADS depression scores and illness perceptions 
were also investigated. Three dimensions of the IPQ-R were found to be 
significantly correlated with HADS depression scores. The ‘identity’ dimension 
of the IPQ-R was found to be positively correlated with HADS depression 
scores (r=0.388, p<0.01), with higher levels of ‘illness identity’ being related to 
higher depression scores. The ‘consequences’ dimension of the IPQ-R was
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also found to be positively correlated (r=0.644, p<0.01), with higher 
consequences of illness being related to higher depression scores on the 
HADS. The ‘emotional representations’ dimension of the IPQ-R was found to 
be positively correlated with HADS depression scores (r=0.331, p<0.05), with 
higher levels of negative emotions about illness being related to higher 
depression scores on the HADS.
The relationship between health-related quality of life and HADS depression 
scores was analysed using correlations. Significant negative correlations were 
found between depression scores and eight dimensions of health-related quality 
of life: physical functioning (r= -0.631, p<0.01), physical role limitations (r= - 
0.622, p<0.01), emotional role limitations (r= -0.674, p<0.01), vitality (r= -0.667, 
p<0.01), mental health (r= -0.716, p<0.01), social functioning (r= -0.518, 
p<0.01), bodily pain (r= -0.642, p<0.01), and general health (r= -0.628, p<0.01). 
Low scores on all of these dimensions indicated low quality of life, and were 
correlated with high levels of depression. The ‘health transition’ dimension was 
positively correlated with HADS depression scores (r=0.438, p<0.01), with 
higher scores indicating a lower quality of life.
All of the above dimensions of coping, illness perceptions and health related 
quality of life were also found to be significantly correlated with HADS anxiety 
scores. However, in the current study the relationship between sexual 
dysfunction and anxiety or depression is considered central. No significant 
relationships were discovered between HADS anxiety scores and the measures 
of sexual dysfunction, therefore, anxiety scores were not investigated in further 
depth.
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It had been intended to conduct regression analyses to investigate the 
relationship between HADS scores and the independent variables of coping, 
illness perceptions, health-related quality of life, and sexual dysfunction. As 
described in the method section, the power and sample size calculations 
showed that a sample of 82 patients was required in order to provide sufficient 
power to conduct such a regression analysis. As the number of participants (52) 
fell considerably short of the required sample size, and given the marked 
colinearity between independent variables, it was not considered valid to 
proceed with regression analysis.
Age
The mean age of the sample was 70.65 years, ranging from 57 years of age to 
86. The sample was divided into three age groups; 65 or less (N=13), 66 to 75 
(N=25) and 76 plus (ISM4). Levels of anxiety and depression on the HADS and 
levels of sexual dysfunction were investigated for the three age groups. Means, 
standard deviations and ranges are displayed in Table 3.
[Insert Table 3 here]
On the HADS anxiety subscale 38.46% of men in the 65 or less group scored 
above the clinically significant cut-off, compared to 16% of men aged 66 to 75, 
and 21.43% in the 76 plus group. On the HADS depression subscale 15.38% 
of men in the 65 or less group scored above clinically significant levels, 
compared to 8% in the 66 to 75 group and 14.29% aged 76 or more. Men in 
the 76 plus age group had a mean score of 27.79 (SD 3.02) on the ASEX, 
compared to 23.36 (SD 5.79) for the 66 to 75 group, and 22 (SD 6.11) for men 
who were 65 or less. Men in the 76 plus group reported the lowest levels of
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sexual functioning on the UCLA PCI with a mean scores of 7.22 (SD 11.38), 
followed by mean in the 66 to 75 group who scored 24.05 (SD 26.05). Finally, 
men aged 65 or less had the highest levels of sexual functioning with a mean 
score of 26.52 (28.33). Men aged 65 of less were most ‘bothered’ by their 
levels of sexual functioning with a mean score of 26.92 (SD 34.55), followed by 
men aged 76 plus who scored an average of 51.79 (SD 45.43). Men in the 66 
to 75 age group reported the least ‘bother’ on the UCLA PCI with a mean score 
of 54 (SD 38.65).
Correlation analyses revealed significant correlations between age and scores 
on the ASEX and the UCLA PCI sexual functioning and sexual bother 
dimensions. Age and ASEX scores were positively correlated (r=0.422, 
p<0.01). Age and UCLA PCI scores were negatively correlated for sexual 
functioning (r= -0.332, p<0.05), with older men reporting lower levels of 
functioning. Age and UCLA PCI scores were positively correlated for sexual 
bother (r=0.281, p<0.05), with older men reporting less bother from their sexual 
problems. No significant relationships were discovered between age and 
anxiety or depression assessed using the HADS.
Discussion
One primary aim of the current study was to investigate levels of self-reported 
anxiety, depression and sexual dysfunction in men following various treatments 
for prostate cancer. Scores for anxiety (Mean=5.23) and depression 
(Mean=3.50) revealed that the majority of patients were below clinically 
significant levels; with 23.1% of patients reporting clinically significant levels of 
anxiety and 11.5% reporting clinically significant levels of depression. These
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prevalence rates are similar to those reported in previous studies [13]. Men 
reported high levels of sexual dysfunction on the ASEX with an average score 
of 24.21 out of 30. Mean scores on the UCLA PCI were low, (20.14 /100) for 
sexual function and (46.63 /100) for sexual bother, with lower scores indicating 
lower levels of functioning. Although previous studies addressing sexual 
problems have been limited and have reported their data in ways which make 
comparison problematic, it is clear that men are reporting high levels of difficulty 
in this area.
The study also aimed to examine any relationships between levels of sexual 
dysfunction and levels of anxiety and depression. It was hypothesized that men 
with higher levels of sexual dysfunction would report higher levels of anxiety 
and depression. This hypothesis was partially supported by the finding that 
HADS depression scores were significantly correlated with ASEX (r=0.326, 
p<0.05) and UCLA PCI sexual function scores (r= -0.330, p<0.05). No 
significant relationships were discovered between HADS anxiety scores and 
measures of sexual dysfunction. Mean ASEX and UCLA PCI sexual function 
scores for men above and below clinically significant cut-offs for HADS 
depression scores were reported. These scores revealed that men who were 
above the clinically significant cut-off for depression on the HADS reported 
higher levels of sexual dysfunction on the ASEX (26.5) compared to those 
below the cut-off (23.91). They also reported lower levels of sexual functioning 
on the UCLA PCI sexual function dimension, 6.94 compared to 21.86.
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Secondary objectives were to assess coping, illness perceptions and health 
related quality of life, and to explore any relationships between these factors 
and levels of anxiety, depression and sexual dysfunction.
It was predicted that men who had lower levels of avoidance type coping, 
assessed by the COPE-B, would have lower levels of anxiety and depression. 
This hypothesis was partially supported by the finding that three dimensions of 
the COPE-B were found to be significantly correlated with HADS depression 
scores. The ‘denial’, ‘substance use’ and ‘venting’ dimensions of the COPE-B 
were positively correlated with HADS depression scores, with higher levels of 
these types of coping being related to higher depression levels. Previous 
studies have linked these dimensions to ‘avoidant’ coping and to higher levels 
of psychological distress [21, 18]. However, not all dimensions on the COPE-B 
that are considered to indicate ‘avoidant’ coping were found to be related to 
HADS depression scores. This finding may suggest that these particular 
dimensions are important for this population.
Illness perceptions were also investigated for this population and it was 
hypothesised that men who perceived themselves to have higher levels of 
illness would have higher levels of anxiety and depression. Three dimensions 
of the IPQ-R were found to be significantly positively correlated with HADS 
depression scores, providing partial support for this hypothesis. The ‘identity’, 
‘consequences’ and ‘emotional representations’ dimensions of the IPQ-R were 
found to be positively correlated with HADS depression scores, with higher 
levels of negative perceptions about illness being related to higher depression 
scores on the HADS. Again, not all dimensions on the IPQ-R were found to be
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related to HADS depression scores, suggesting that these particular dimensions 
may be important in prostate cancer patients.
Finally it was hypothesised that men who reported higher levels of ‘health 
related quality of life’ would have lower levels of anxiety and depression. 
Significant correlations were found between HADS depression scores and all 
nine dimensions of health-related quality of life. These findings provided partial 
support for the hypothesis, in that increased levels of depression appeared to 
be related to lower levels of health-related quality of life.
Following these analyses the relationships between age and levels of anxiety, 
depression and sexual dysfunction were also investigated. On the HADS 
anxiety and depression sub-scales a higher percentage of men who were 65 or 
less scored above clinically significant cut-offs than men who were over 66 to 
75, or 76 and over. Mean scores on the ASEX and UCLA PCI sexual 
functioning and sexual bother dimensions, and correlation analyses of these 
scores with age, revealed that although older men experienced higher levels of 
sexual dysfunction and lower levels of sexual functioning they appeared to be 
least ‘bothered’ by their sexual difficulties. Previous studies have reported that 
men who were 65 or less were significantly more interested in sex and more 
sexually active than men who were over 65 years of age [30]. This may help to 
explain why older men seemed to be less ‘bothered’ by their sexual problems 
and reported lower levels of anxiety and/or depression.
Correlation analyses revealed that seventeen factors were significantly 
correlated with HADS depression scores, namely; ASEX scores, UCLA PCI
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sexual function scores, COPE-B ‘denial’, ‘substance use’ and ‘venting’ 
dimensions, IPQ-R ‘identity’, ‘consequences’ and ‘emotional representations’ 
dimensions, and all nine health related quality of life dimensions on the SF-36. 
Initially a regression analysis to investigate associations between HADS 
depression scores and these factors was planned. However, only fifty-two 
participants were recruited to the study resulting in insufficient numbers of 
participants per independent variable [21]. During data analysis it also emerged 
that colinearity between and within measures was a problem. All of the 
dimensions on the SF-36 were found to be significantly correlated with each 
other, and with the ‘identity’ and ‘consequences’ dimensions of the IPQ-R. 
These difficulties led to the conclusion that regression analyses were not 
appropriate in this instance.
Lim itations
The current study has a number of methodological limitations. Firstly, the final 
sample in the study consisted of 52 participants. This number was lower than 
the required sample size initially calculated which, for two dependent and four 
independent variables, was 82 participants [27].
Secondly, the response rate of 36.7% means that just under two thirds of men 
approached did not return their questionnaires. No information was available 
regarding the men who did not complete the questionnaires, making it difficult to 
comment on the representativeness of the sample, and therefore, the 
generalisability of the findings.
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Thirdly, the current study used a cross-sectional design which allowed for self- 
report data to be collected for a single time point. In order to provide a more 
comprehensive picture of prostate cancer patients at different stages of 
treatment and follow-up it would have been preferable to use a longitudinal 
design. This would have allowed the researcher to examine any fluctuations of 
psychological distress and levels of sexual functioning throughout the prostate 
cancer patient’s journey.
Finally, during this study men were not analysed by treatment group. The type 
of treatment used may have had an impact on the levels of sexual dysfunction, 
anxiety and depression. Previous studies have found significant differences 
between treatment groups when looking at levels of psychological distress [13]. 
However, due to the very complex nature of prostate cancer treatments and the 
small number of patients in this study it was not considered appropriate to 
analyse participants according to treatment type.
Future Research & Clinical Applications
Future research may firstly aim to address some of the methodological 
problems described for the current study, such as, using a prospective design, 
recruiting a large sample, using methods that may result in an increased 
response rate, and analysing participants in terms of treatment group.
In terms of clinical applications previous studies have identified that the 
psychological needs of prostate cancer patients are often unmet [30]. The 
current study has started to identify certain factors that may be linked to 
psychological distress and sexual dysfunction in prostate cancer patients. The
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finding that depression, but not anxiety, is related to sexual problems may help 
clinicians to identify men who are likely to need input. Further research into 
levels of anxiety, depression and sexual dysfunction at different stages of 
prostate cancer diagnosis and treatment would help to identify when men are 
most ‘at risk’ of low mood and when input would be most valuable.
Looking at other factors associated with psychological distress in prostate 
cancer patients such as; coping, illness perceptions, and health-related quality 
of life, has revealed a number of dimensions that appear to be related to higher 
levels of depression. Assessing for particular styles of coping and perceptions 
of illness may assist clinicians in identifying patients who may be more ‘at risk’ 
of high levels depression and allow them to intervene at an early stage in the 
cancer treatment process.
The issue of sexual functioning is still somewhat ‘taboo’ and clinicians reported 
that many men did not seem comfortable to discuss this issue during 
appointments. Anecdotal reports revealed that many clinicians also did not 
often discuss sexual functioning or psychological distress in follow-up 
appointments with patients. It is hoped that the current study will help to raise 
awareness of the issues faced by prostate cancer patients and encourage 
clinicians to ask routinely about sexual functioning and psychological distress in 
consultations.
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Table 1 -  Demographic data for sample (n=52) including mean age, age 
range, ethnic background, relationship status, education and employment 
status
Range Mean
Age:
65 years of age or less 
66 to 75 
76 years of age or more
57-86
25%
48.1%
26.9%
70.65
Ethnic Background: White/Caucasian
Black/African-American 
Asian/Pacific Islander
96.2%
1.9%
1.9%
Relationship: Living with spouse/partner 
In relationship, not living together 
Not in relationship
86.5%
I.9%
II.5%
Education: Grade School or less
Some High/Technical School 
High/Technical School Graduate 
Some College 
College Graduate 
Graduate/Professional School after College
15.4%
26.9%
13.5%
11.5%
7.7%
25%
Employment: Yes, full-time 
Yes, part-time 
No, looking for a job 
No, retired 
No, disabled
9.6%
7.7%
1.9%
78.8%
1.9%
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Table 2 -  Summary statistics including mean, standard deviation and 
range for outcome measures; ASEX, HADS, COPE-B, IPQ-R, SF-36 and 
UCLA PCI
Mean SD Range
1) ASEX 24.21 5.65 12-30
2) HADS Anxiety 5.23 4.32 0-18
Depression 3.50 3.39 0-13
3) COPE-B Self distraction 4.02 2.07 2-8
Active coping 4.77 1.97 2-8
Denial 2.62 1.22 2-7
Substance use 2.50 1.26 2-8
Use of emotional support 5.02 2.17 2-8
Use of instrumental support 3.60 1.82 2-8
Behavioural disengagement 2.92 1.43 2-7
Venting 3.37 1.46 2-7
Positive reframing 4.31 1.71 2-8
Planning 4.29 2.02 2-8
Humour 3.96 2.04 2-8
Acceptance 5.98 2.01 2-8
Religion 4.00 2.36 2-8
Self blame 3.15 1.60 2-8
4) IPQ-R Identity 2.04 2.81 0-10
Timeline (acute/chronic) 22.00 5.16 8-30
Consequences 18.04 4.54 10-26
Personal control 17.35 3.61 7-25
Treatment control 17.35 2.79 11-23
Illness coherence 17.58 4.13 10-25
Timeline cyclical 8.88 3.84 4-19
Emotional representations 15.79 4.70 6-26
Causes 38.58 8.56 20-56
5) RAND SF-36 Physical functioning 71.54 25.39 0-100
Role limitations (physical) 62.26 33.51 0-100
Role limitations (emotional) 74.45 26.27 16.67-100
Vitality 53.97 27.37 0-100
Mental health 75.58 17.28 25-100
Social functioning 77.16 27.42 0-100
Bodily pain 71.97 29.55 0-100
General health 60.05 21.47 15-95
Health Transition 46.63 25.26 0-100
6) UCLA PCI Urinary function 78.80 24.24 11.60-100
Bowel function 83.21 20.50 23.75-100
Sexual function 20.14 24.59 0-96.88
Urinary bother 75.48 28.65 0-100
Bowel bother 78.37 31.71 0-100
Sexual bother 46.63 40.53 0-100
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Table 3 -  Means, standard deviations and ranges for measures of anxiety, 
depression and sexual dysfunction for three age groups; 65 or less, 66 to 
75 and 76 plus
Mean SD Range
65 or less
N=13
1) ASEX 22.0 6.11 14-30
2) HADS Anxiety
Below cut off (7 or less) 
Above cut off (8+)
5.85
61.54%
38.46%
5.19 0-16
Depression
Below cut off (7 or less) 
Above cut off (8+)
3.62
84.62%
15.38%
3.45 0-10
3) UCLA PCI Sexual function 26.52 28.33 0-78.13
Sexual bother 26.92 34.55 0-100
66-75
N=25
1) ASEX 23.36 5.79 12-30
2) HADS Anxiety
Below cut off (7 or less) 
Above cut off (8+)
4.64
84%
16%
3.50 0-13
Depression
Below cut off (7 or less) 
Above cut off (8+)
2.68
92%
8%
3.16 0-12
3) UCLA PCI Sexual function 24.05 26.05 0-96.88
Sexual bother 54.00 38.65 0-100
76 plus
N=14
1) ASEX 27.79 3.02 20-30
2) HADS Anxiety
Below cut off (7 or less) 
Above cut off (8+)
5.71
78.57%
21.43%
4.95 0-18
Depression
Below cut off (7 or less) 
Above cut off (8+)
4.86
85.71%
14.29%
3.53 0-13
3) UCLA PCI Sexual function 7.22 11.38 0-38.50
Sexual bother 51.79 45.43 0-100
121
Chapter 5: Single Case Research Proposal
An Experimental Analysis Of Self-Injurious Behaviour In An Individual With A
Moderate Intellectual Disability.
(Part Two bound separately)
Prepared in accordance with guidelines for ‘single case research proposal’ in 
Doctorate of Clinical Psychology Research Training Folder
Rebecca Clifford
Section of Psychological Medicine
University of Glasgow
Division of Community Based Sciences
Gartnavel Royal Hospital
1055 Great Western Road
Glasgow
G12 0XH
Submitted in partial fulfilment of the requirements of the degree of Doctorate in
Clinical Psychology
122
Title
An Experimental Analysis Of Self-Injurious Behaviour In An Individual With A 
Moderate Intellectual Disability.
Abstract
This study aimed to look at the relationship between certain ecologically valid 
situations and self-injurious behaviour in an individual with a moderate 
intellectual disability. Challenging behaviour has been identified as an ongoing 
issue for carers and service providers for people with intellectual disabilities, 
with between 10 and 15% of people with intellectual disabilities displaying some 
form of challenging behaviour (Emerson, 1998). Tasse (2006) stated that 
understanding the function of challenging behaviour was a critical component to 
developing an effective intervention plan. Following on from these 
recommendations a baseline assessment of the case was completed with a 
view to investigating the context of the self-injurious behaviour. The 
participant’s most frequent form of self-injurious behaviour was face punching, 
therefore, the study was designed to focus on situations when this behaviour 
occurred. From baseline information it appeared that the individuals’ self- 
injurious behaviour was less frequent in certain situations, for example, when 
sitting alone. Following the completion of a baseline assessment an 
experimental analysis of behaviour was carried proposed involving four 
ecologically valid conditions: alone, with staff, with other residents, with staff 
and residents. The findings of the baseline assessment are discussed, along 
with methods and for the proposed experimental analysis. Possible 
applications for findings of the experimental analysis are also discussed.
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Appendices
Appendix 1 -  Small Scale Service Related Project
Appendix 1.1 - An Audit of the Evening Clinics running in the East Area of 
Glasgow Clinical Psychology Service: A Management Presentation
An Audit of the Clinical Background
Psychology Evening Clinics
running in the East of Glasgow
• Clinical Psychology Waiting List
A Management Report • Review - Audit Scotland (2002)
• Managing Waiting Times: Good Practice
Guide - Scottish Executive (2003)
Audit Questions Audit Questions
• How many appointments were available? • How many times did people attend?
• How many new people were seen?
• How many people were discharged?
• How many appointments were taken up?
• How many people were offered day-time 
sessions?
• How many people attended? 
* -
• What was the immediate impact on the 
waiting list?
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Method Results
• Sample -  224 patients • 242 new patients taken off waiting list
• Waiting List Initiative Database
• 56% Attended
• 22% DNA
• Patient Information Management System
• 15% Cancelled
• Descriptive Statistics
• Day-time Service: 64% Attended 
23% DNA 
13% Cancelled
Results Conclusions & Recommendations
• 29% discharged after clinics
• 33% offered further input
• Small reduction in number of people on 
waiting list after each clinic
• 3% reduction in waiting list after 1s1 clinic
• 15% reduction in waiting list after 2nd clinic
• Further investigation of factors impacting 
upon waiting list
* •
• Consider alternative uses of evening 
clinics
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Appendix 2.2 - Study Flowchart
406 Studies considered not 
relevant to review question 
based on abstract
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1 Study not peer reviewed
9 Studies non-English 
language
5 Studies letters, editorials or 
reviews
32 Studies
436 Studies identified using 
search strategy
2 Studies Prostate Cancer 
not primary diagnosis
12 Studies included in 
review
3 Studies no outcome 
measure for anxiety and/or 
depression
2 Further studies identified 
from reference lists & hand 
searches
30 Studies considered 
relevant to review question 
based on abstract
20 Studies did not meet 
inclusion criteria upon further 
inspection of full article
Appendix 2.3 - Methodological Checklist
Author
Year
Title
1 - Introduction
Not 
Addressed, 
Not reported 
or Not 
applicable
Poorly
Addressed
Well 
Covered or 
Adequately 
Addressed
1.1 Study addresses 
appropriate & clearly 
focused question
0 1 2
1.2 Study has clearly 
stated aims
0 1 2
1.3 Study has dearly 
stated hypotheses
0 1 2
2 - Participants
2.1 Clearly defined 
study population
0 1 2
2.2 Sample size 
stated
0 1 2
2.3 Sample 
demographics stated
0 1 2
2.4 Power calculation 
to justify sample size
0 1 2
2.5 Control group 0 1 2
2.6 Cases & controls 
taken from
0 1 2
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comparable
populations
2.7 Assignment to 
treatment groups is 
randomised
0 1 2
2.8 Inclusion criteria 
stated
0 1 2
2.9 Exclusion criteria 
stated
0 1 2
2.10 Study indicates 
how many people 
asked to take part did 
so
0 1 2
2.11 Study states 
how many people 
dropped out before 
study was completed
0 1 2
3 - Procedures
3.1 Outcome 
measures clearly 
defined
0 1 2
3.2 All relevant 
outcomes are 
measured in a 
standard, valid & 
reliable way
0 1 2
3.3 Evidence from 
other sources is used 
to demonstrate that 
the method of 
outcome assessment 
is valid & reliable
0 1 2
3.4 If non­
standardised 
measures, measure 
described, and
0 1 2
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reliability & validity 
stated
4 -  Results & 
Analysis
4.1 Results clearly 
stated
0 1 2
4.2 Appropriate 
statistical tests used
0 1 2
4.3 All participants 
are analysed in the 
groups
0 1 2
4.4 Where study is 
carried out at multiple 
sites results are 
comparable for all 
sites
0 1 2
4.5 Confidence 
intervals have been 
provided
0 1 2
4.6 Main potential 
confounders are 
identified & taken into 
account in the design 
& analysis
0 1 2
Score 
(Out of 48)
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Appendix 3.1 -  IHTAB ethics confirmation
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From:
To:
Cc:
Date:
Andrea Harkin
0403467C@student.gla.ac.uk
1 2 /20 /06  05:28 pm
Subject: Re: IHTAB
Attachments:
Hi Rebecca
I can confirm that your proposal was discussed at our recent IHTAB meeting 
onn 14th November 2006 and that this was approved. No support was required 
from the Clinical Trials Unit.
Best of luck with your application.
Kind regards
Andrea Harkin
Head of Trial Co-ordination
Cancer Research UK Clinical Trials Unit, Glasgow
(partner in CaCTUS - Cancer Clinical Trials Unit Scotland)
38 Church Street
1st Floor E Block
Western Infirmary
Glasgow G11 6NT
Tel: 0141 211 8558 
Fax: 0141 211 6239 
http: / /w w w . crukctuglasgow.org
Andrea
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Appendix 4.1 -  Glasgow West Local Research Ethics Committee letter
North Glasgow University Hospitals 
Division
Greater
Glasgow
W est Glasgow Ethics Committee 2
Western Infirmary 
Dumbarton Road 
Glasgow 
G11 6NT
Telephone: 0141 211 6238 
Facsimile: 0141 211 1920
20 February 2007
Miss R Clifford
Trainee Clinical Psychologist 
Section of Psychological Medicine 
Division of Community Based Sciences 
Gartnavel Royal Hospital 
1055 Great Western Road, Glasgow 
G12 0XH
Dear Miss Clifford
Full title of study: Life After Treatment for Prostate Cancer: Levels of
Anxiety, Depression, and Sexual Dysfunction.
REC reference number: 06/S0709/145
The Research Ethics Committee reviewed the above amended application at the meeting 
held on 20 February 2007.
Ethical opinion
The Committee reviewed the amendments contained within your letter dated 10th January, 
2007 and approved these.
The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 
documentation.
Ethical review of research sites
The favourable opinion applies to the research sites listed on the attached form. 
Conditions of approval
The favourable opinion is given provided that you comply with the conditions set out in the 
attached document. You are advised to study the conditions carefully.
Approved documents
The documents reviewed and approved at the meeting were: 135
Document version Date
Application 5.2 23 November 2006
Investigator CV 01 November 2006
Protocol 1.4 23 November 2006
Covering Letter 23 November 2006
Covering Letter 10 January 2007
Questionnaire 08 January 2007
Participant Information Sheet 1.0 23 November 2006
Participant Information Sheet 1 23 November 2006
Participant Consent Form 1 23 November 2006
Participant Consent Form 1.0 23 November 2006
Response to Request for Further Information 10 January 2007
Letter from Dr S Porteous Field Supervisor 12 January 2007
Summary CV for supervisor 23 November 2006
Research governance approval
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final research governance approval from the R&D Department for the relevant NHS 
care organisation.
Membership of the Committee
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
| 06/S0709/145 Please quote this number on all correspondence
With the Committee’s best wishes for the success of this project 
Yours sincerely
Andrea H Torrie
Ethics Manager -  West Glasgow LRECs
Email: andrea.torrie@northglasgow.scot.nhs.uk
Enclosures: List of names and professions of members who were present at the
meeting and those who submitted written comments 
Standard approval conditions SL-AC2 
Site approval form (SF1)
Copy to: M r Brian Rae
NHS Greater Glasgow and Clyde Research and Development 
Directorate
Research and Development Directorate
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Appendix 4.2 - Participant Information Sheet
UNIVERSITY
GLASGOW
Title: Life After Treatment for Prostate Cancer: Levels of Anxiety, Depression,
and Sexual Dysfunction.
We would like to invite you to take part in a research study. We are interested 
in learning about your experiences of life after being diagnosed with and treated 
for Prostate Cancer You have been given this pack as you may be able to help 
us in this study. My name is Rebecca Clifford, I am a Trainee Clinical 
Psychologist and I will be running the study. Before you decide if you would like 
to take part it is important for you to understand why the research is being done 
and what it will involve. Please read this information carefully.
What is the research about?
We are interested in understanding your experiences of life after being treated 
for prostate cancer. In particular: your mood, how you have coped, if your 
sexual functioning has changed, what you think about your illness, and your 
quality of life. We are also interested in how all of these things are related to 
each other.
This kind of research is important in developing a better understanding of the 
psychological needs of men with prostate cancer. The study will be run from 
November 2006 to June 2007.
Why have I been asked to take part?
We are asking men who have been diagnosed with and treated for prostate 
cancer to participate in this study. A total of approximately 80 men are being 
asked to take part.
Do I have to take part?
You do not have to take part in this study. If you decide to take part you will be 
asked to sign a consent form. The consent form is a way of making sure you 
know what you have agreed to. If you decide to take part you are still free to 
withdraw from the study at any time and you do not have to give a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive.
What do I have to do?
If you would like to take part please complete the two consent forms and seal 
them in the separate consent form envelope. One consent form will be kept on 
file and the other will be sent back to you. Next complete the five 
questionnaires in this pack. Put all of the completed forms into the stamped 
addressed envelope in your pack and post it to Gartnavel Royal Hospital. 
Please put your hospital number on top of each questionnaire, NOT your name.
P S Y C H O L O G IC A L  M E D IC IN E  
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What is the downside?
It is possible that the questionnaires may cover topics that are difficult or 
distressing for you to think about. If you report high levels of anxiety or 
depression in the questionnaires your Clinical Nurse Specialist and Consultant 
will be notified.
What are the possible benefits of taking part?
The information we learn from the study will help us plan future research and 
develop psychological services for men with prostate cancer. If you are 
experiencing high levels of distress this research will allow you to access 
appropriate additional services should you wish to.
Will my taking part in this study be kept confidential?
You have written your hospital number on top of each questionnaire, not your 
name. Your participation in this study will be kept confidential. The only time 
when this would not be the case is if you reported high levels of distress, when 
your Clinical Nurse Specialist and Consultant would be informed.
What will happen to the results of the research study?
Your Consultant and Clinical Nurse Specialist will have a summary of the 
results of the study for you to read should you wish. The final results and 
conclusions of the study will be published in a scientific journal and will form 
part of my qualification in Clinical Psychology. Your identification will not be 
included in any publication.
Who is organising and funding the research?
The University of Glasgow.
Who has reviewed the study?
The study has been reviewed by the Department of Psychological Medicine to 
ensure that it meets standards of scientific conduct and has been reviewed by 
NHS Greater Glasgow Research Ethics Committee to ensure that it meets 
standards of ethical conduct.
Contact Details
If you have any queries please speak to your Consultant, your Clinical Nurse 
Specialist or myself using the details below.
Name -  Rebecca Clifford, Trainee Clinical Psychologist
Telephone -  0141 211 0607
E-mail -  0403467c@student.gla.ac.uk
Thank you very much for reading this and for any further involvement you
may have with the study.
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Appendix 4.3 - Consent Form
Title of Project: Rebecca Clifford’s Research Project 
Name of Researcher: Rebecca Clifford
Patient Hospital Number: ........................................
t R  I T M
UNIVERSITY
° f
GLASGOW
Please tick box
1. I confirm that I have read and understood the information 
sheet for the above study.
1. I understand that my participation is voluntary and I am free to 
withdraw at any time, without giving a reason, and without my
medical care or legal rights being affected.
1. If I report significant levels of anxiety or
depression I understand that my Clinical Nurse Specialist, 
and Consultant will be informed
1. I agree to take part in the above study
Print Name 
Signature -
Date -------
Address —
Please sign both consent forms and send them back separately in the 
small envelope in your pack. Thank you.
P S Y C H O L O G IC A L  M E D IC IN E  
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Appendix 4.4 -  Arizona Sexual Experiences Scale (ASEX)
HOSPITAL NUMBER.........................................................................................
ARIZONA SEXUAL EXPERIENCES SCALE (ASEX)-MALE
For each item, please indicate your OVERALL level during the PAST WEEK, including 
TODAY.
1. How strong is your sex drive?
1 2 3 4 5 6
extremely very somewhat somewhat very weak no sex drive
strong strong strong weak
2. How easily are you sexually aroused (turned on)?
1 2 3 4 5 6
extremely very somewhat somewhat very never aroused
easily easily easily difficult difficult
3. Can you easily get and keep an erection?
1 2 3 4 5 6
extremely very somewhat somewhat very never
easily easily easily difficult difficult
4. How easily can you reach an orgasm?
1 2 3 4 5 6
extremely very somewhat somewhat very never reach
easily easily easily difficult difficult orgasm
5. Are your orgasms satisfying?
1 2 3 4 5 6
extremely very somewhat somewhat very can’t reach
satisfying satisfying satisfying unsatisfying unsatisfying orgasm
COMMENTS:
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Appendix 4.5 -  Countersigned consent form letter
UNIVERSITY
° f
GLASGOW
Life After Treatment for Prostate Cancer: Levels of Anxiety, Depression,
and Sexual Dysfunction.
Dear Sir,
Thank you very much for taking part in the above research study.
Please find enclosed the counter signed consent form for your reference. 
You do not need to take any further action regarding this study.
We wanted to know about your experiences of life after being treated for 
prostate cancer.
In particular: your mood, how you have coped, if your sexual functioning has 
changed, what you think about your illness, and your quality of life. We also 
wanted to know how all of these things were related to each other.
Your answers will help us to develop a better understanding of the 
psychological needs of men with prostate cancer. The information we learn 
from this study will help us plan future research and develop psychological 
services for men with prostate cancer.
Your Consultant and Clinical Nurse Specialist will have a summary of the 
results of the study for you to read should you wish. This summary will be 
available in December 2007.
Thank you very much for taking part.
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